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The roles of UBXNs in the regulation of antiviral immune responses have not been much 
explored. Previous work in our lab identified UBXN1 as a negative regulator of the retinoic acid-
inducible gene-I (RIG-I) like receptors (RLR) pathway and UBXN3B as a positive regulator of 
stimulator-of-interferon Genes (STING) -mediated immune responses. In this study, I aimed to 
determine the member of UBXNs as a positive regulator of ribonucleic acid (RNA) virus infection-
induced innate immune responses. By using an interferon stimulated response element 
(ISRE)-driven luciferase reporter assay that monitors the activity of type I/III interferon (IFN)-
induced janus kinase (JAK) - signal transducer and activator of transcription proteins (STAT) 
signaling, I found that over expressed UBXN6 synergized with RIG-I, IFN-β or IFN-λ to enhance 
antiviral immune responses.    
 I further used small interfering RNA (siRNA) and clustered regularly interspaced short 
palindromic repeats (CRISPR)-Cas9 technology to abrogate UBXN6 function, aiming to establish 
the function of UBXN6 in viral infection and JAK-STAT signaling. By polymerase chain reaction 
(PCR) array I found that UBXN6-deficiency led to a reduction in type I/III IFN-induced gene 
expression, which was validated by quantitative reverse transcriptase polymerase chain reaction 
(q-RT-PCR). Also, RNA virus replication was increased in UBXN6-deficient when compared to 
UBXN6-sufficient cells, which was accompanied by a significant reduction in IFN-β and IFN-λ.  
Lastly, I decoded the mechanism by which UBXN6 regulates the JAK-STAT pathway. I observed 
that IFN-β-stimulated STAT1 phosphorylation was impaired in UBXN6-deficient cells. By co-
immunoprecipitation techniques and mass spectrometry analysis, I identified that following IFN-β 
stimulation UBXN6 interacted with protein arginine methyltransferase 5 (PRMT5) that is known to 
xv 
 
interact with JAK1/2. Our results demonstrate that UBXN6 positively regulates JAK1-STAT1/2 





1 Introduction and Background: 
 
 The series of events generated by the host immune system against a virus 
determines the fate of viral infection. Both the innate and adaptive responses are induced 
after viral infection consecutively. The major component of innate immune responses 
includes an anatomical barrier, inflammation, complement cascade, and several types of 
white blood cells. The most critical innate antiviral mechanism is the production of 
Interferon, which is secreted and act in an autocrine and paracrine fashion. The 
recognition of interferon leads to the expression of hundreds of interferon-stimulated 
genes (ISGs). This primarily leads to either production of antiviral proteins like protein 
kinase R (PKR) that inhibit viral protein synthesis or the production of 2', 5'-oligoadenylate 
synthetase family that degrades viral RNA. The adaptive immune responses are 
characterized by two main components namely humoral immunity generating specific 
antibodies and cell-mediated effectors against a pathogen. The primary function of the 
acquired immune system is the specific recognition of non-self-antigens presented in 
context with Major histocompatibility complex (MHC) molecules, generation of tailored 
responses to eliminate pathogen or pathogen-infected cells, and the development of 
immunologic memory. Together, the innate and adaptive immune responses hinder viral 




1.1 Pathogen pattern recognition receptors 
 The host innate immune response sets within a few hours of viral infection. The 
degree and magnitude of such response decide the outcome of infection, containment or 
dissemination. Host cytoplasmic pattern recognition receptors (PRR) initiate the antiviral 
immune response that recognizes pathogen-associated molecular patterns (PAMPs) of 
viral nucleic acid. The primary PRRs families are Toll-like receptors (TLR), retinoic acid-
inducible gene-I (RIG-I) like receptors (RLR) and Nucleotide-binding and oligomerization 
domain (NOD)-like receptors (NLR) (Figure 1). The binding of PAMPs to PRRs activates 
downstream signals to stimulate the transcription of a broad spectrum of genes to 
produce cytokines and chemokines (Wilkins and Gale, 2010) . Production and secretion of 
interferon including type-I interferon (IFN-I)/ IFN-αβ or type II interferon (IFN-II), or type 
III interferon (IFN-III)/ IFN-λ is a central event. The IFN pathway signaling is central to the 
generation of an antiviral state through ISGs in virus-infected and non-infected cells (S.-Y. 
Liu et al., 2011) . IFNs act as the first line of cell-intrinsic defense against viral infection 






Figure 1:  TLR, RLR, and NLR signaling pathways.  
Three known innate immune sensors; TLRs, RLRs, and NLRs recognize harmful signals such 
as PAMPs, DAMPs, non-self nucleic acid, change in ionic or redox state at the cell surface, 
in the endosome or the cytoplasm. The recognition by TLRs and RLRs activate secondary 
messengers, which ultimately transduce the signal for activation and nuclear 
translocation of transcription factors such as IRFs, NFκB, and AP-1 that 
stimulate expression of cytokines like IFN-α/β, TNF and pro-IL-lβ.  The NLRs further 
promotes the assembly of the caspase-1 inflammasome and subsequent maturation of IL-
1β from pro-IL-1β (As adapted from Theofilopoulos et al. 2010).  
Abbreviations: Danger-associated molecular pattern (DAMP), interleukin-1 (IL-1), 
interferon regulatory factor (IRF3), nuclear factor kappa-light-chain-enhancer of activated 
B cells (NFκB), Activator protein 1 (AP-1)   
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1.1.1 The RLR pathway 
 
 The two RLRs, RIG-I/ DExD/H-Box Helicase 58 (DDX58) and melanoma 
differentiation-associated 5 (MDA5) / interferon induced with helicase C domain 1 (IFIH1), 
sense double-stranded viral RNA (Onoguchi et al., 2011) . Engagement of viral RNA leads 
to a conformational change in RLR. In the open conformation, the amino-terminal 
caspase recruitment domain (CARD) is available to interact with mitochondrial antiviral 
signaling protein, mitochondrial antiviral signaling protein (MAVS) (Seth et al., 2005) .  
Activated MAVS undergoes topological change to expose its TNF receptor-associated 
factor 3 (TRAF) -interacting motif (TIM) domain for binding to TRAF3 and TRAF6 (Paz et 
al., 2011) . This leads to activation of canonical I-kappa-B kinase (IKKs) and related kinases 
like tumor necrosis factor receptor-associated factor  (TRAF)-family member-associated 
NF-B activator (TANK)-binding kinase 1 (TBK1) (Pichlmair et al., 2006) . MAVS is also 
involved in assembling NF-kappa B Essential Modulator (NEMO) and TBK1 complex on the 
mitochondrial surface. MAVS is then degraded by proteasomal machinery to release this 
complex into the cytosol. Further, TBK1 phosphorylates interferon regulatory factor (IRF3) 
(Castanier et al., 2012) . The phosphorylated IRF3 dimerizes and translocates to the 
nucleus to bind to the ISRE promoter to trigger IFN production (Z. Wang et al., 2016) . 
Peroxisome also provides a platform for co-localization of activated MAVS. It induces IFN-
independent antiviral response characterized by rapid and short-term protection (Dixit et 




1.1.1.1 Regulation of the RLR signaling: 
 
 Stimulation of both innate and adaptive immune pathways is crucial to host 
defense against infection. At the same time, these pathways are subjected to stringent 
regulation by cellular factors to maintain an appropriate degree of immune responses and 
to prevent cellular damage. All signaling pathways and activated proteins must be 
regulated, and the RLR pathway is no exception to this. Stringent regulatory mechanisms 
are needed to prevent any deleterious effect on the host. 
 
1.1.1.2 Regulation of immune pathways by post-translation modifications 
 
 Post-translation modifications (PTM) is another mechanism by which various 
molecules involved in immune signaling are modified and regulated for its activation or 
destruction. PTMs increase the functional diversity of the proteome by the covalent 
addition of functional groups or proteins, proteolytic cleavage of regulatory 
subunits, or degradation of complete proteins. These modifications include 
phosphorylation, glycosylation, ubiquitination, nitrosylation, methylation, 
acetylation, lipidation and proteolysis, and influence almost all aspects of normal 







 Ubiquitination is one of the universal posttranslational protein modifications 
occurring in the cell. Ubiquitin, an evolutionarily highly conserved 76 amino acid 
polypeptide, is covalently attached to lysine residues of target proteins through a highly 
organized and hierarchical group of enzymes. As there are seven lysine residues on 
ubiquitin, it is possible that during ubiquitination, new ubiquitin molecules added to one 
of the seven lysine residues of the previously conjugated ubiquitin. This process, called 
polyubiquitination, is a standard cellular signal. Depending on the usage of the lysine 
residues on ubiquitin, various linkage-specific ubiquitinations could happen; which 
include K6, K11, K27, K29, K33, K48, K63, and M1. K48 and K63 linkage-specific 
ubiquitinations are the most effective forms of polyubiquitination; In contrast to the 
proteolytic role of the K48-specific linkage, the K63-specific linkage has been 
demonstrated to regulate a variety of nonproteolytic cellular functions, including 
deoxyribonucleic acid (DNA) damage repair, stress responses, and inflammatory 





Figure 2: Types of ubiquitination and their role in cellular processes. 
Mono-ubiquitination of the target protein is involved in protein interaction and 
localization. Poly-ubiquitination of K-48 and K-11 was found to be required for 
proteasomal degradation. Ubiquitination of K-63 chain plays a role in NF-κB activation, 
DNA repair, and lysosomal targeting. Linear chain M1 poly-ubiquitination was found to 
activate NF-κB signaling. The function of various other types ubiquitination including K-6, 
K-29, K-33, K-27, heterogenous chain, and branched chain is not known As adapted 




1.1.1.3 Regulation of RLR signaling by host cellular proteins 
 
 The levels of RIG-I are subjected to transcriptional and post-transcriptional 
regulations, which maintain its appropriate response. Post-translational modifications 
activate or deactivate the protein function, which ultimately decides the fate of the 
signaling pathway. An E3 ligase including tripartite motif-containing (TRIM)-25 binds to 
the CARD domain of RIG-I, resulting in the conjugation of K-63 ubiquitin chain to the 
lysine 172 of the CARD domain. Ubiquitination of RIG-I is critical for its activation and 
binding to MAVS that ultimately activate IFN production (Matsumiya and Stafforini, 2010) 
. TRIM25 B30.2 domain interacts with both CARD1 and CARD2 domains of RIG-I to open 
the N terminal α helix (D'Cruz et al., 2018) . 
 MAVS is a central mediator of the RLR pathway and subjected to the regulation by 
host factors and is also the target of viral proteins (F. Liu and Gu, 2011) . The host protein 
NLR family member X1 (NLRX1) co-exists with MAVS on the outer mitochondrial 
membrane. It was found to be a potent inhibitor of MAVS-mediated IFNβ promoter 
activity (Moore et al., 2008) . Another protein, Poly C binding protein2 (PCBP-2) is induced 
after viral infection. It recruits E3 ligase, atrophin-interacting protein 4 (AIP4), which 
polyubiquitinates MAVS leading to proteasomal degradation (You et al., 2009) . Thus, 
NLRX1 and PCBP2 are involved in the negative regulation of MAVS-mediated signaling.  
 Another host protein HSCARG was found to regulate IFNβ production negatively 
(Figure 3). Following the viral infection, HSCARG interacts with TRAF3 and cooperates 
with ovarian tumor (OTU) deubiquitinase Ubiquitin Aldehyde Binding (OTUB1) to remove 
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Lys63-linked polyubiquitin chain from TRAF3. This further decreases the recruitment of 
IKKε and results in decreased phosphorylation of IKKε and IRF3, and finally reduces the 
production of IFN-β (Peng et al., 2014) . Some host proteins like ring finger protein 5 
(RNF5), Itchy ubiquitin E3 protein ligase (ITCH), myeloid differentiation primary response 
88 (MyD88), and interleukin1 receptor-associated kinase (IRAK) participates in the 
regulation of RIG-I and TLR pathway (Heaton et al., 2016) . 
 
1.1.1.4 Regulation by TRIM proteins 
 
 Upon recognition of RNA viruses, RIG-I induces the synthesis of inflammatory 
cytokines and type I IFNs. Briefly, RIG-I recruits the adapter MAVS and activates NF-κB 
(p50/RelA heterodimer) and IRF3 via IKKα/IKKβ/NEMO and TBK1/IKKi, respectively. The 
transcription factor is translocated to the nucleus and promote IFN transcription, 
translation, and secretion. The secreted IFNs activate the STAT1/STAT2/IRF9 complex via 
JAK or tyrosine kinase (TYK) to induce ISGs, including TRIM proteins. 
 More than 60 TRIM proteins are known in human and mice. IFN-I/ IFN-II induces 
several TRIM proteins that are involved in the tight regulation of antiviral immune 
pathways. Many TRIM proteins like TRIM 5, 8, 11, 21, 25, 32, 63 have E3 ubiquitin ligase 
activity  (Keiko Ozato et al., 2008a) . Several cellular target proteins and their positive or 
negative regulation by TRIM have been identified (Figure 4). TRIM25 induces the 
ubiquitination of RIG-I to promote downstream signaling. TRIM23 enhances NEMO 
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function by promoting ubiquitination and TRIM27 interferes with IKKα/IKKβ and 
TBK1/IKKi activation. TRIM21 is involved in the inhibition of IKKβ and IRF7 and positive or 
negative regulation of IRF3 and IRF8. TRIM56 enhances STING function during DNA sensor 
signaling pathways for the induction of type I IFNs (Kawai and Akira, 2011) . Collectively, 
due to the diversity of TRIM proteins, they are capable of either stimulation or inhibition 




Figure 3: A model of TRAF3-dependent regulation of RLR signaling pathway by HSCARG. 
Following the viral infection, HSCARG interacts with TRAF3 and OTUB1 to decreases the 
recruitment of IKKε and results in decreased phosphorylation of IKKε and IRF3, and finally 






Figure 4: Regulation of RIG-I and DNA sensor signaling by TRIM proteins. 
TRIM25, TRIM23, and TRIM56 positively regulate RIG-I, NEMO, and STING, respectively. 
TRIM27 negatively regulates IKK complex or TBK1 activity. TRIM21 shown to inhibit 
NEMO-IKK complex and IRF7 activity and able to regulate both positively or negatively 




1.2 Interferon response   
 
 As a result of viral recognition and downstream signaling, fibroblast and 
monocytes secrete IFN-I. IFN-Is bind the cell surface receptor IFN-α/β receptor (IFNAR1/2) 
heterodimer, which then recruits, two JAK molecules. JAK phosphorylates IFNAR and 
STAT, which then dimerize and enter the nucleus and transcribe ISGs. Several ISGs directly 
inhibit virus infection by targeting the early or late stage of the viral life cycle in the host. 
This fast and amplified response combats viral infection (Schneider et al., 2014) . 
 
1.2.1 Interferon types and receptors 
 
 Type I IFNs comprise the most significant IFN class, and all human cells are capable 
of IFN-I production(Siegal et al., 1999) . This class involves IFN-α, IFN-β, IFN-ε, IFN-κ, and 
IFN-ω, which are all grouped on chromosome 9. IFN-I is recognized by the heterodimeric 
receptor complex containing IFNAR1 and IFNAR2 subunits (Figure 5). The different types 
of IFN-I show differential tissue expression level and binding affinity for the IFNAR1/2 
receptor complex (Pestka et al., 2004) .  
 
 There is only one type II IFN, IFN-γ. It is a homodimeric protein recognized by the 
IFN-γ receptor complex (IFNGR).  Two IFNGR1 subunits initiate binding to IFN-γ followed 
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by the recruitment of two auxiliary IFNGR2 subunits and results in receptor enactment 
(Walter et al., 1995) . IFN-γ production is to a great extent confined to immune cells. 
However, the IFNGR1/2 receptors are broadly distributed, and almost all cell types are 
responsive to IFN-γ (Valente et al., 1992) . Two primary functions of IFN-II are immune 
regulation and connecting innate immune responses to adaptive immunity. Broadly, IFN-II 
is involved in up-regulation of pathogen recognition, antigen processing and presentation, 
antiviral state, inhibition of cellular proliferation and effects on apoptosis, activation of 
microbicidal effector functions, immunomodulation, and leukocyte trafficking (Schroder 
et al., 2004) . 
 The more recently discovered IFN-III subfamily is comprised of IFNL1/ IFNλ1/ 
interleukin (IL)-29, IFNL2/ IFNλ2/ IL-28A, IFNL3/ IFNλ3/ IL-28B. All three IFN-λs signal 
through the same heterodimer receptor complex composed of IFNLR1 and interleukin -10 
receptor 2 (IL-10R2) (Sheppard et al., 2003) . IFN-λs may interfere with virus infection by 
various mechanisms including direct antiviral effect, or as a modulator of IFN-α-induced 
signaling via the suppressor of cytokine signaling 1 (SOCS) and the ubiquitin-specific 
peptidase 18 (USP18) inhibitory feedback loops (Syedbasha and Egli, 2017) . IFN-III 
showed potent antiviral Encephalomyocarditis virus (EMCV) activity in vitro but was 
unable to reduced infection in the murine model when treated singularly. On the other 
hand, IFN-III treatment prevents the disease pathogenesis by blocking herpes simplex 
virus-2 (HSV-2) replication in the vaginal mucosa (Ank et al., 2006) . IL28B contributes to 
Hepatitis C virus (HCV) resistance and is known to be upregulated by interferon and by 





Figure 5: IFN-I, IFN-II, and IFN-III signaling. 
IFN-I, IFN-II, and IFN-III bind to distinct receptors namely IFNAR1- IFNAR2 dimer, IFNGR1- 
IFNGR2 tetramer, and IFNLR1-IL10R2 dimer, respectively.  Association of IFN with the 
receptor complex activates TYK2 and JAK1 kinases, which phosphorylate and dimerize 
STAT1 and STAT2.  Phosphorylated STAT1-STAT2 dimer in association with IRF9 generates 
the ISGF3 complex. The IFN and receptor binding could also generate phosphorylated 
STAT1 dimer as a transcription factor. The transcription factors, ISGF3 or STAT1 dimer, 






Figure 6: Antiviral innate immune signaling involves three following significant events. 
First, recognition of viral DNA/ RNA by PRRs to activate IFN production. Second, the 
association of secreted interferon with IFNR to express hundreds of ISGs. Third, the action 
of ISGs as antiviral effectors or regulate these two pathways positively or negatively As 
adapted from (Schneider et al., 2014)   
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1.2.2 Interferon response- JAK-STAT pathway 
 
 Association of IFN with the receptor complex activate JAK-STAT signaling pathway 
(Figure 6).  Briefly, IFNRs specifically recognize IFN and dimerize two receptor subunits, 
which activates TYK2 and JAK1 kinases, which phosphorylate and dimerize STAT1 and 
STAT2.  Phosphorylated STAT1-STAT2 dimer in association with IRF9 generates the ISGF3 
complex. The IFN and receptor binding could also generate phosphorylated STAT1 dimer 
as a transcription factor. The transcription factors, ISGF3 or STAT1 dimer, translocate to 
the nucleus and bind to ISRE to activate transcription of several ISGs. 
 
1.2.2.1 Janus Kinases (JAKs) 
 
 The known JAKs include JAK1, JAK2, JAK3, and TYK2 (Kawamura et al., 1994)  
(Stark et al., 1998) . They comprise the catalytic kinase domain and regulatory pseudo-




 There are seven known mammalian STATS, STAT1, STAT2, STAT3, STAT4, STAT5A, 
STAT5B, and STAT6. They have homologous regions of SRC homology 2 (SH2) domain, 
DNA-binding domain, and a transactivation domain. The amino-terminal region of 
18 
 
STATs is involved in regulating STAT activity, such as the formation of STAT tetramers 
(Xu et al., 1996)  and tyrosine dephosphorylation (K. Shuai et al., 1996) . 
 
1.2.2.3 Interferon-stimulated genes: ISG 
 
 ISGs are involved in various effector function including directly targeting 
molecules required during the pathogen life cycle, maintaining cellular homeostasis by 
regulating antiviral state, pro-apoptotic proteins leading to cell death (Schneider et al., 
2014) . ISGs are capable of enhancing pathogen recognition properties as well as 
regulating signaling through the JAK-STAT pathway.  Some PRRs and IRFs expression is 
amplified by IFN, leading to enhanced pathogen recognition. A subset of ISGs is capable of 
IFN-independent activation to counteract pathogen-mediated innate immune evasion 
strategies (Iwasaki, 2012) .  
 A recent study aimed to decipher molecular mechanisms of ISG network identified 
104 ISGs interactions and 1401 cellular partners. Various ISGs interact with some shared 
partners suggesting their central role in ISG mediated antiviral immune response. While 
few others attribute to specific interactome, suggesting a discreet role in particular viral 
infection (Hubel et al., 2019) . 
 Interferon-induced transmembrane protein-1 (IFITM1), IFITM2, and IFITM3 
coordinate to induce antiviral activity in the interferon-stimulated cell. Endosomal IFITM3 
combines with entering viral particle and inhibits viral fusion with lysosomal membrane 
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and thus release of the viral genome to the cytoplasm for replication. IFITM3 binding to 
the virus is specific and require s-palmitoylation (Ritz et al., 2011) . Although S-
palmitoylation enhances IFITM3 membrane affinity and antiviral activity, ubiquitination 
decreases its localization with endolysosomes and antiviral activity in influenza infection 
(Yount et al., 2012) . 
 Oligoadenylate synthetase (OAS) detects cytosolic PAMPs leading to the synthesis 
of 2′-5′-oligoadenylates, which then act as intracellular second messengers to activate 
latent RNaseL. Activated RNase L degrades viral RNA, which can be sensed by RLRs, 
ultimately amplifying IFN response (Chakrabarti et al., 2011) .  
 They are two Myxovirus resistance (Mx) proteins, Mx1/ MxA, and Mx2/ MxB, 
which are related to dynamin-like large guanosine triphosphatases (GTPases) family of 
protein. Mx proteins are found to potently block viral entry by trapping incoming viral 
nucleotides and preventing its cellular movement. Mx1 contains a central stalk domain 
and a GTPase effector domain, which are both essential for self-oligomerization and 
formation of ring-like structures that bind to and impose conformational changes on the 
target protein (Klockow et al., 2002) . Mx2 potently inhibits human immunodeficiency 
virus 1 (HIV-1) and HIV-2 entry (Kane et al., 2013) . It keeps the reverse-transcribed 
genome from reaching its nuclear destination, thereby ultimately inhibiting chromosomal 
integration, which is an essential event of the HIV-1 replication cycle (Z. Liu et al., 2013) . 
 IFN stimulation induces several TRIM family of proteins. TRIMs are composed of 
60 members and mainly function as an E3 ubiquitin ligase (K. Ozato et al., 2008b) . One of 
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the most studied TRIM as an ISG is TRIM5α, a potent inhibitor of HIV-1 entry (Stremlau et 
al., 2004) . TRIM5α binds to HIV-1 capsid, uncoating and exposing the viral nucleoprotein 
complex (Campbell et al., 2008) . Another protein TRIM22 inhibits expression of the HIV-1 
long terminal repeats (Tissot and Mechti, 1995) . It also inhibits trafficking of the HIV-1 
Gag protein to the host cell plasma membrane, resulting in reduced viral production (Barr 
et al., 2008) . TRIM22 has also been shown to inhibit multiple viruses by various 
mechanisms. It inhibits transcription from the core promoter of hepatitis B virus (HBV), 
blocks EMCV replication by promoting ubiquitination of the viral 3C protease, and targets 
influenza A virus nucleoprotein for proteasomal degradation (Schneider et al., 2014) . 
 Activation of dsRNA dependent PKR via IFN stimulation leads to a significant 
reduction in host mRNA production/ translation. In contrast, PKR is found to be crucial for 
the integrity of newly synthesized IFN mRNA to generate an optimal host antiviral 
immune response. Also, PKR is involved in the degradation of the inhibitor of κB (IκB),  
resulting in activation of the NF-κB signaling pathway (Munir and Berg, 2013) .  
 
1.2.2.4 IFN desensitization 
 
 Interferon stimulation induces transcription of two genes, IFN-IND1 and IFN-IND2 
within 30 minutes to 2 hours. Shortly after that cells undergo an IFN- desensitized state. It 
allows cells to recover from the IFN signaling expenditure (Larner et al., 1986) . Diverse 
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1.2.2.5 Regulation of interferon response by Post-translation modifications  
 
 PTM activates/ deactivates proteins rapidly leading to a quick response in signal 
transduction. PTM regulating JAKs and STATs functions includes phosphorylation, 
methylation, ubiquitination, and ISGylation.  
 Tyrosine phosphorylation of JAK2 is required for its efficient ubiquitination. 
JAK2 is ubiquitinated and rapidly degraded, which can be enhanced by IL-3 and IFN-γ. 
The SOCS box of SOCS1, which interacts with elongins B and C, is required for the 
ubiquitination of JAK2. So, the stability of JAK2 seems to be regulated by a SOCS1-
mediated ubiquitin-proteasome pathway (Ke Shuai and Liu, 2003) . 
 In a process known as ISGylation, a small IFN-induced gene 15 (ISG15) that is 
ubiquitin-like protein is covalently attached to target proteins through a series of steps 
that mirror the ubiquitination pathway. ISG15 ISGylates JAK1 and STAT1 to regulate 
their function (Malakhova et al., 2003) . The removal of ISG15 conjugates (de-ISGylation) 
is performed by the isopeptidase activity of an ISG, USP18. (Malakhov et al., 2002)  USP18 
is a chief player in maintaining long-lasting desensitization of IFN-I signaling by ISGylation-
dependent and independent manner. In an ISGylation independent mechanism, USP18 
binds to the intracellular domain of IFNAR2, which prevents the binding of 
JAK1 (Malakhova et al., 2006) .  
 The intracellular conserved domain of IFN receptor, Serine 532, is phosphorylated 
and subsequently ubiquitinated by Skp, Cullin, F-box protein (SCF) E3 ubiquitin ligases. 
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However, the exact mechanism and outcome of ubiquitination are not clearly 
understood. 
 The tyrosine phosphorylation of JAKs and STATs catalyzes their activation. 
Independently, serine phosphorylation is observed on STAT1, STAT3, STAT4, STAT5A, 
and STAT5B (Levy and Darnell, 2002) . STAT1 is phosphorylated on Serine 727 by one of 
several kinases including extracellular signal-regulated protein kinase (ERK), p38, JUN 
N-terminal kinase (JNK), and protein kinase Cδ (PKCδ) (Decker and Kovarik, 2000) .  
 The arginine 31 methylation of STAT1 occurs constitutively, independently of 
tyrosine or serine phosphorylation. It increases the DNA-binding activity of STAT1, 
possibly due to inhibition of the interaction of PIAS1 with non-methylated STAT1 
(Mowen et al., 2001) . The ubiquitin-proteasome pathway regulates polyubiquitination 
of STAT1 (T. K. Kim and Maniatis, 1996) . It has been shown that STAT1 can be modified 
by small ubiquitin-related modifier (SUMO)lyation on Lys703, which can be strongly 
enhanced by PIAS proteins (Rogers et al., 2003) .  
 
1.2.2.6 Regulation of IFN response by host proteins 
 
 Three primary JAK-STAT regulators include Suppressors of Cytokine Signaling 
(SOCS), Protein Inhibitors of Activated STATs (PIAS) and Protein Tyrosine Phosphatases 
(PTPs) (Figure 7). 
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There are eight known SOCS proteins including CIS (cytokine-inducible SH2 domain 
protein) and SOCS1–SOCS7 (Hilton, 1999) . SOCS proteins bind to phosphorylated 
tyrosine residues, on either the JAKs or IFNRs, inhibiting JAK activity and STAT-binding. 
The C terminus of SOCS recruits proteins involved in receptor ubiquitination and 
proteasome degradation. SOCS proteins are induced early in the IFN response and play an 
essential role in early IFN desensitization (Hong and Carmichael, 2013) . The SOCS box 
can also bind to ubiquitin E3 ligase elongins B and C, suggesting that it targets signaling 
proteins for proteasomal degradation (Zhang et al., 1999) .  
 The mammalian PIAS family consists of four members including PIAS1, PIAS3, 
PIASX, and PIASY (K. Shuai, 2000) . PIAS has been shown to inhibit STAT-mediated gene 
activation by three possible mechanisms. PIAS1 and PIAS3 prevent the binding of the 
STAT dimers to DNA. While PIASX and PIASY might act as transcriptional co-repressors 
of STAT by recruiting other co-repressor proteins such as histone deacetylase (HDAC). 
PIAS proteins can regulate STAT1 by SUMO-lyation (Ke Shuai and Liu, 2003) . 
 PTPs regulate JAKs and exhibit specificity to negative regulation. Two SH2 
domains-containing PTPase is SH-PTP1 and SH-PTP2 (Neel, 1993) . Another PTP, known 
as CD45 can directly bind and dephosphorylate all JAKs (Irie-Sasaki et al., 2001) . Two 
related PTPs, PTP1B and T cell protein tyrosine phosphatase (TCPTP), were shown to 







Figure 7: Regulators of the JAK-STAT pathway. 
 suppressor of cytokine signaling (SOCS) proteins, protein tyrosine phosphatases 
(PTPs), and Protein inhibitor of activated STAT (PIAS) As adapted from (Ke Shuai and Liu, 





 The human genome encodes at least 13 ubiquitin-regulatory-X (UBX)-domain-
containing proteins (UBXN) (Alexandru et al., 2008)  (Figure 8). Throughout the species, 
individual UBXNs are well conserved. Based on their protein domain composition, the 
human UBXNs are sub-classified into two main groups: the ubiquitin-associated (UBA)-
UBX proteins and UBX-only proteins. The UBA domain motifs are predicted to interact 
with target proteins for nonredundant proteasomal degradation. The UBX domain of all 
UBXNs might bind and influence the function of an ATPase associated with diverse 
cellular activities (AAA)-ATPase, p97, which is also called as valosin-containing protein 
(VCP) (Schuberth and Buchberger, 2008) . VCP is a multifunctional protein involved in 
cellular processes like Endoplasmic-reticulum-associated protein degradation (ERAD), 
autophagy, endosomal sorting, mitochondrial and cytoplasmic protein degradation 
(Chapman et al., 2011) . The UBA-UBX domain proteins could bind to E3 ligase and 
recognize K-11 and K-48 polyubiquitin chains, demonstrating their role in ubiquitin-
dependent proteasomal degradation pathway. Association of UBXNs with the binding 
partners like p97 and E3 ubiquitin ligases strongly suggests their role in the regulation of 
global protein turnover and cellular signaling. 
 Ubiquitin-dependent proteasomal degradation is one of the most studied protein 
degradation mechanisms. The role of VCP in ERAD is well established in this process. 
Proteomic networking analysis of VCP and its UBX domain cofactors revealed that various 
UBA-UBX domain-containing proteins form complexes with VCP and are also associated 
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with E3 ubiquitin ligases. UBXNs have diverse roles, and the substrate-specific 
degradation is carried out via specific UBXN-VCP complex. Interaction of VCP, nuclear 
protein localization protein 4 (NPL4), and Ubiquitin Recognition Factor In ER-Associated 
Degradation 1 (UFD1) with the substrate hypoxia-induced factor 1-α (HF-1α) and E3 ligase 
requires UBXN7. In the native state, the UBA and UBX domains are bound to each other. 
The UBX domain serves as a binding platform for VCP only when the UBA domain is 
associated with a ubiquitinated substrate (Alexandru et al., 2008) . 
 The N-terminal domain of VCP binds multiple regulatory cofactors including the 
UFD1/NPL4 heterodimer and UBXNs. The crystal structure of the UBXN3A/ FAS-
associated factor 1 (FAF1), UBX domain in complex with the VCP N domain, reveals that 
the signature Phe-Pro-Arg motif known to be crucial for interactions of UBX domains with 
VCP adopts a cis-proline configuration. Moreover, UBXN3A and UBXD7 only bind to VCP-
UFD1/NPL4, but not free VCP, thus demonstrating a hierarchy in VCP-cofactor 
interactions (Hanzelmann et al., 2011) . 
 The connections among VCP and the PUB [PNGase (peptide N-
glycosidase)/ubiquitin-associated] area of PNGase, the UBX space of p47, and the UBD 
(ubiquitin D) space of NPL4 have been fundamentally described. The UBX and UBD are 
auxiliary homologs that share comparable VCP-restricting modes. It is conceivable that 
different proteins that contain a UBX/UBX-like space likewise associate with VCP using 
comparable systems. Moreover, a few short VCP-collaborating themes, for example, VCP-
binding motif (VBM), VCP-interacting motif (VIM) and SHP, have been recognized as of 
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late and are additionally shared between VCP connectors, implying that proteins having 
the equivalent VCP-restricting theme may likewise share standard VCP-restricting 
components (Yeung et al., 2008) . 
 The overview of each UBXN including its aliases, size, domains and functions are 
discussed further (Table 1). 
1.3.1 UBXN1 
 
 Various UBXNs were found to be involved in decreased lentiviral and retroviral 
production. UBXN1, UBXN9, and UBXN11 interfere with NF-κB pathway by binding to 
Cullin 1 (CUL 1), which inhibits the inhibitor of kappa B (IκBα) degradation. UBXN1 was 
found in being involved in murine embryonic cell development, cell adhesion, immune 
response pathways (Hu et al., 2017) .  
 UBXN1 was shown to interfere with RNA virus-induced IFN-I response while 
potentially increasing replication of viruses such as vesicular stomatitis virus (VSV), 
Sendai, West Nile, and dengue virus. At the molecular level, UBXN1 targets MAVS and 
blocks MAVS oligomerization, and disrupts the MAVS/TRAF3/TRAF6 signalosome, 
ultimately affecting IFN production (P. Wang et al., 2013) . Similarly, UBXN1 was found to 
regulate NF-κB signaling.  UBXN1, which contained both ubiquitin-associated and 
ubiquitin regulatory X (UBX) domains acts as a negative regulator of TNFα-triggered NF-κB 
activation. Over-expression of UBXN1 inhibited TNFα-triggered NF-κB activation, although 
knockdown of UBXN1 had the opposite effect. UBX domain-containing proteins usually 
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act as VCP cofactors. However, knockdown of VCP barely affected UBXN1-mediated NF-
κB inhibition. At the same time, we found that UBXN1 interacted with cellular inhibitors 
of apoptosis proteins (cIAPs), E3 ubiquitin ligases of RIP1 in the TNFα receptor complex. 
UBXN1 competitively bound to cIAP1, blocked cIAP1 recruitment to TNF receptor 1 
(TNFR1), and sequentially inhibited receptor-interacting serine/threonine protein kinase 1 
(RIPK1) polyubiquitination in response to TNFα. These findings demonstrate that UBXN1 
is an essential negative regulator of the TNFα-triggered NF-κB signaling pathway by 
mediating cIAP recruitment independent on VCP (Y. B. Wang et al., 2015) . 
 A recent study demonstrated that the induction of interferon is potentially 
suppressed by Nipah virus V protein via UBXN1. Briefly, Nipah virus V protein interacts 
with the UBX domain of UBXN1 via its proximal zinc-finger motif in the C-terminal 
domain. Also, the level of UBXN1 is increased in Nipah infection, by suppressing its 
proteolysis. Additionally, Nipah virus V protein suppressed RIG-I and MDA5-dependent 
interferon signaling by stabilizing UBXN1 and increasing the interaction between MAVS 
and UBXN1 (Uchida et al., 2018) . 
 UBXN1 was shown to negatively modulate ERAD. This requires the ability of 
UBXN1 to bind both polyubiquitin and VCP. Moreover, the binding of UBXN1 with VCP is 
positively regulated by polyubiquitin binding of the UBX protein. It was found that UBXN1 
also negatively regulate the VCP-dependent processing required for degradation of a 
cytosolic, non-ERAD, substrate. Additionally, UBXN1 protect polyubiquitin from the 
activity of deubiquitinases, such as ataxin-3, that are necessary for efficient ERAD. Thus, 
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UBXN1 inhibits protein degradation mediated by VCP complexes by protecting 
polyubiquitin chains from deubiquitination (LaLonde and Bretscher, 2011) . 
 Another recent study demonstrates that UBXN1 is negatively regulated by 
epidermal growth factor receptor mutation vIII (EGFRvIII), which play a significant role in 
glioblastoma cancer. The upregulation of H3K27me3 mediates the down-regulation of 
UBXN1 in the presence of EGFRvIII. EGFRwt/vIII activate NF-κB by suppressing UBXN1 
expression (Huang et al., 2017) . Another cancer study revealed that UBXN1 polypeptide 
recognizes auto-ubiquitinated breast cancer type 1 susceptibility protein (BRCA1) via the 
UBA domain. The recognition is made in a bipartite interaction in which the UBA domain 
of UBXN1 binds K6-linked polyubiquitin chains conjugated to BRCA1 and the C-terminal 
domain of UBXN1 bind the BRCA1/ BRCA1 Associated RING Domain 1 (BARD1) 
heterodimer in a ubiquitin-independent fashion. The E3 ligase activity of BRCA1/BARD1 is 
drastically reduced in the presence of UBXN1. Thus, UBXN1 regulates the enzymatic 




 UBXN2A binds to Mortalin (mot2) and prevents p53-mot2 complex formation. 
Mot 2 inactivates the tumor silencer p53's transcriptional and apoptotic function by 
cytoplasmic sequestration of p53 in select malignancies. Interrupted p53-mot 2 
interactions can control the development of disease cells in colon cancer. The interaction 
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also discharges p53 from cytosolic sequestration, safeguarding the tumor silencer 
elements of p53. Thus UBXN2A acts as a home defense response protein, which can 
reconstitute inactive p53-dependent apoptotic pathways. Inhibition of mot2-p53 
interaction by UBXN2A is an attractive therapeutic target in mot2-elevated colon cancer 
(Sane et al., 2014) . 
 UBXN2A also binds to alpha3, alpha4 subunits of neuronal nicotinic acetylcholine 
receptors (nAChRs). This binding affects alpha3 ubiquitination and proteasomal 
degradation. Thus, UBXN2A affects the stability and cell surface number of these 




 VCP complexes with UBXN2B in the cytosol and localizes to the Golgi and 
Endoplasmic reticulum (ER). VCP-UBXN2B complex showed membrane fusion activity 
(Uchiyama et al., 2006) . Another study showed that phosphorylation of UBXN2B on 
Serine-56 and Threonine-59 by Cdc2 at mitosis, and this phosphorylated UBXN2B does 
not bind to Golgi membranes.  
UBXN2B phosphorylation inhibits the VCP/UBXN2B pathway. These results 
demonstrate that UBXN2B phosphorylation on Serine-56 and Threonine-59 is essential for 
Golgi disassembly at mitosis (Kaneko et al., 2010) . 
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 UBXN2B regulates the orientation of the spindle, which is a crucial step in cell 
division process and determines tissue morphogenesis and development of an organism. 
Briefly, spindle orientation is regulated via Gαi-LGN- nuclear mitotic apparatus protein 
(NuMA) complex. UBXN2B inhibits cortical NuMA levels via the protein phosphatase 1 
(PP1) and its regulatory subunit Repo-Man. In metaphase, UBXN2B negatively regulates 
the accumulation of NuMA, resulting in lower cortical NuMA levels and correct spindle 
orientation  (B. H. Lee et al., 2018) . 
 PP1 exhibits different functional reaction with many substrates by the assembly of 
alternative PP1 holoenzymes. Newly formed holoenzyme needs to be disassembled by 
the VCP AAA-ATPase to promote exchange for the substrate. UBXN2B acts as an adaptor 
in this process. The UBXN2B shp1, eyc, and p47 (SEP) domain interact with inhibitor-3 (I3) 
without the need for ubiquitination. Thus, VCP-UBXN2B complex function in a ubiquitin-
independent manner in PPI biogenesis (Weith et al., 2018) . 
 In a recent study, VCP inhibitor analogs were evaluated for their ability to inhibit 
the ATPase activity against VCP, VCP-UBXN2B or VCP- Npl4-Ufd1 heterodimer (NU). The 
protein sequence of UBXN2B is 50 % identical to that of p47. However, unlike p47, 
UBXN2B does not significantly change the potencies of most of the tested analogs, 






 UBXN3A associates with Fas-associated death domain protein (FADD) and caspase 
8. The death effector domains (DEDs) of caspase-8 and FADD interacts with the amino 
acid 181-381 region of UBXN3A. Its over-expression in Jurkat cells causes apoptotic 
death. It is suggested that UBXN3B is a member of multiple Fas-death-inducing signaling 
complex (Fas-DISC), acting upstream to caspase 8 (Ryu et al., 2003) . Also, UBXN3B can 
drive breast cancer metastasis. UBXN3A destabilizes transforming growth factor β 
receptor II (TGF-βRII) on the cell surface by recruiting the VCP/E3 ligase complex. AKT 
phosphorylates UBXN3B at ser582, which abrogates UBXN3A activity and increases cell 
surface receptor availability. It leads to heightened TGF-β response and epithelial-to-
mesenchymal transition (EMT) and metastasis (Xie et al., 2017) . 
 UBXN3A positively regulates RNA virus-induced antiviral responses. Briefly, it 
competitively binds with NLRX1, which liberates MAVS from NLRX1-inhibited state. The 
free MAVS can bind to RIG-I and activate downstream signaling (J. H. Kim et al., 2017) . 
UBXN3A can also regulate MAVS activity by a different mechanism. TRIM31 is an E3 ligase 
that catalyzes lysine 63-linked poly-ubiquitination of MAVS. UBXN3A can antagonize the 
poly-ubiquitination and aggregation of MAVS by competing with TRIM31. Also, viral 
infection triggers the kinase IKKɛ directly which phosphorylates serine 556 of UBXN3A and 
triggers UBXN3A de-aggregation. Moreover, Ser556 phosphorylation promotes UBXN3A 
lysosomal degradation, consequently relieving UBXN3A-dependent suppression of MAVS 
(Dai et al., 2018) . 
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 The UBXN3A N-terminal UBA domain recognizes Lys(48)-ubiquitin linkage to 
recruit polyubiquitinated proteins and its C-terminal UBX domain interacts with VCP. VCP 
association to the C-terminal UBX domain regulates ubiquitin binding to the N-terminal 
UBA domain. The VCP-Npl4-Ufd1 complex is known as the machinery required for 
endoplasmic reticulum-associated degradation. UBXN3A binds to VCP-Npl4-Ufd1 complex 
via its UBX domain and polyubiquitinated proteins via its UBA domain to promote ERAD 
(J. J. Lee et al., 2013) . 
 UBXN3A is involved in negative regulation of NF-kappaB activation. UBXN3A binds 
to NF-kappaB p65 via its death effector domain (DED)-interacting domain (amino acids 
181-381), where DEDs of the Fas-associated death domain protein and caspase-8 interact 




 UBXN3B plays a role in the regulation of lipid metabolism. UBXN3B is capable of 
sensing unsaturated fatty acids (FAs). This exposure alters UBXN3B structure. It ultimately 
results in the inhibition of the synthesis of triglyceride (TGs) from diacylglycerols (DAGs) 
(J. N. Lee et al., 2010) . Another study showed that trafficking of UBXN3B to lipid droplets 
(LD) is restricted when it associates with ER-resident pseudo-protease UBA domain 
containing 2 (UBAC2). Also, LD size is increased when VCP is recruited to LD via UBXN3B 
association. This has resulted from an inhibition of adipose triglyceride lipase (ATGL) 
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activity and dissociation of co-activator comparative gene identification (CGI-58) 
(Olzmann et al., 2013) .  
 Hepatocyte-specific UBXN3B knockout mice on a high-fat diet showed significantly 
lower serum triglyceride and secreted very low-density lipoprotein (VLDL) as compared to 
wild type mice. Lipidated apolipoprotein B (ApoB) was accumulated in lipid droplet of 
UBXN3B knockout mice hepatocytes. The accumulation could ultimately result in 
periportal macrovascular steatosis (Imai et al., 2015) . UBXN3B was shown to target HMG-
CoA reductase (HMGCR) to its proteasomal degradation. It affects rate-limiting enzymatic 
catalysis of the mevalonate pathway. Thus, UBXN3B is also capable of regulating de novo 
sterol biosynthesis to control cholesterol synthesis (Loregger et al., 2017) .  
 Our recent study demonstrated that UBXN3B positively regulates STING signaling. 
STING was first identified as a DNA sensor and recently shown to be involved in anti-viral 
responses against RNA viruses also. Ubxn3b knockout mice, like Sting knockout mice, are 
highly susceptible to lethal herpes simplex virus 1 (HSV-1) and VSV infection, which is 
correlated with deficient immune responses. Functional studies demonstrate that 
UBXN3B interacts with both STING and activate STING signaling via ubiquitination, 
dimerization, trafficking. Thus, UBXN3B is involved in the positive regulation of STING 






 UBXN4/UBXD2/erasin is an ER and nuclear envelope integral membrane protein 
with both its N- and C-termini facing the cytoplasm or nucleoplasm. A single 21-amino-
acid sequence located near the C-terminus is necessary and sufficient for localization of 
UBXN4 to the ER. UBXN4 protein expression increases during stress. It binds VCP via its 
UBX domain and triggers ERAD substrate CD3delta. Also, UBXN4 was found to 
accumulates preferentially in neurons undergoing neurofibrillary degeneration in 
Alzheimer's disease (Liang et al., 2006) . Knockdown of UBXN4, which serves a binding 
platform for VCP and ubiquitin in human cells slowed the degradation of two classical 
ERAD substrates. In Caenorhabditis elegans, ubiquitin and UBXN4 are ER stress-response 
genes that are regulated by the ire-1 branch of the unfolded protein response pathway. 
Loss of ubiquitin or UBXN4 activates ER stress, increases the accumulation of 
polyubiquitinated proteins, and shortens the lifespan of worms. These results 





 UBXN6 is one of the essential cofactors of VCP involved in the endolysosomal 
localization leading to autophagy. Upon endosome and lysosome rupture, VCP is 
recruited along with cofactors UBXN6, phospholipase A-2-activating protein (PLAA), and 
deubiquitinating enzyme YOD1. This endo-lysosomal response complex acts downstream 
of K-63 ubiquitination and p62 recruitment. It stimulates autophagy by selectively 
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removing K-48 ubiquitinated proteins from damaged lysosomal repertoire (Papadopoulos 
et al., 2017) .  
 VCP in the association of several co-factors involved in the cellular processes that 
maintain homeostasis.  Mutations at the interface between the N-terminus and the first 
of two ATPase areas (D1 and D2) in VCP deregulate the ATPase action and cause a 
multisystem degenerative disorder, inclusion body myopathy in Paget disease of bone 
and frontotemporal dementia/amyotrophic lateral sclerosis. These mutations found to 
prominently weaken the VCP- UBXN6 interaction during caveolin-1 (CAV-1) 
endolysosomal sorting. The N-terminus of UBXN6 is critical and can be classified as 
intrinsically disordered. The N-terminal helices 1 and 2 of UBXN6 bind with VCP motifs. 
Additionally, two distant epitopes on the VCP N-domain that include disease-associated 
residues and additional interaction between UBXN6-N terminus and the D1D2 barrel of 
VCP were identified. Functionally, binding of UBXN6 to VCP led to a reduction of ATPase 
activity and partial protection from proteolysis. Together, this study indicates that UBXN1 
N terminus intercalates into the VCP and UBXN6-N terminal D1 interface, thereby 
modulating interdomain communication of VCP domains and its activity (Trusch et al., 
2015) . 
 CAV1 is a plasma membrane-resident sorted to endosome and lysosome by VCP-
UBXN6 complex. Six lysine residues in the N-terminal region of CAV1 get ubiquitinated, 
which then bind and recruit VCP-UBXN6 complex to endosomes (Kirchner et al., 2013) . 
VCP missense mutation leads to degenerative disease in humans, in which muscle-specific 
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caveolin-3 accumulates in sarcoplasmic pools and specifically delocalizes from the 
sarcolemma. The formation of CAV-VCP-UBXN6 complex is compromised by a disease-
associated mutation, which leads to defective endosomal sorting of ubiquitylated CAV-1. 
Thus UBXN6 activity was found to be affected by VCP mutation (Ritz et al., 2011) . 
 VCP, in association with the Ufd1-Npl4 heterodimer as an adaptor, plays an 
essential role in ERAD. Several UBXNs recruit ubiquitinated substrates to VCP/Cdc48 by 
binding both VCP/Cdc48 and other ERAD components such as ubiquitin ligases. UBXN6 is 
involved in ERAD process. UBXN6 is a cytosolic protein that interacts with VCP and Derlin-
1. UBXN6 overexpression in cells causes selective dissociation of Ufd1 from VCP, resulting 
in inhibition of mutant cystic fibrosis transmembrane conductance regulator (CFTR) 
degradation by ERAD (Nagahama et al., 2009) . 
 The AAA ATPase complex is known as VCP in mammals, and the yeast homolog is 
Cdc48. It is involved in various cellular pathways, including membrane fusion, protein 
folding, protein degradation and activation of membrane-bound transcription factors. 
This broad range of cellular involvement is executed via specific co-factors of VCP. UBXN6 
is one of the co-factor of VCP. It localizes to the cytoplasm and nucleus and is highly 
expressed in centrosomes. Phosphorylation of the penultimate tyrosine residue in VCP 
completely abolishes UBXN6 interaction. Ternary complexes of UBXN6, p47 and VCP were 
detected in vitro. Inhibition of UBXN6 expression by siRNA did not affect the degradation 
of bulk protein or a model substrate of the ERAD pathway, indicating that UBXN6 directs 
VCP activity to specialized functions in vivo (Madsen et al., 2008) . 
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 UBXN6 is a cofactor of VCP and possesses two binding domain namely UBX and 
PUB. The PUB domain mediates robust binding to the C-terminus of VCP, while the UBX 
domain does not contribute to VCP binding. Also, VCP possesses additional binding site in 
UBXD1 that competes with the p47 cofactor for binding to the N domain of VCP. This 
bipartite binding mode suggests that UBXN6 could be an effective regulator of VCP 
cofactor interactions (Kern et al., 2009) . 
 UBXN6 shows a relationship with lectin mannose-binding 1, also called as ER-Golgi 
intermediate compartment 53 kDa protein (ERGIC-53), a hexameric type I integral film 
protein. The UBXD1-ERGIC-53 association requires the N-terminal ten deposits of UBXD1 
and the C-terminal cytoplasmic 12 amino corrosive tail of ERGIC-53. Utilization of VCP and 
E1 protein inhibitors show that development among UBXD1 and ERGIC-53 requires the 
ATPase movement of VCP, however not ubiquitin change. Moreover, a UBXD1-Rab3GAP 
affiliation requires the ERGIC-53 restricting space ofUBXN6. Confinement contemplates 
showing that UBXD1 modules the sub-cell dealing of ERGIC-53, including elevating 
development to the cell film. Thus, VCP-UBXD1 tweaks the dealing of ERGIC-53-
containing vesicles by controlling the connection of transport factors with the cytoplasmic 
tail of ERGIC-53 (Haines et al., 2012) . 
 In Huntington disease mitochondrial outer membrane protein Myeloid cell 
Leukemia sequence-1(MCL1) is degraded extensively via VCP. UBXN6 specifically 
recognizes and bind to targets MCL1 and co-factors with VCP to extract MCL1 from 
mitochondria. In the mutant Huntington gene, VCP-UBXN6 complex can significantly 





 UBXN7 can participate in the degradation of misfolded or damaged proteins in the 
VCP-mediated ubiquitin-proteasome system (UPS). UBXN7 binds to ubiquitinated 
substrates via its UBA domain and interacts with VCP N-terminal domain through its UBX 
domain to recruit VCP or the VCP core complex (VCP/NPL4/UFD1). The crystal structural 
superpositions suggest that dimerization of UBXN7 via an intermolecular disulfide bond 
could interfere with the formation of the VCP-UBXN7 complex. Interestingly, UBXN7 may 
have a cooperative effect on VCP interaction with UFD1 (Z. H. Li et al., 2017) . 
 Human UBXN7 mediates VCP interaction with the transcription factor HIF1α that 
is actively ubiquitylated in normoxic cells by a CUL2-based E3 ligase, CRL2. UBXN7 
interaction with cullins is independent of ubiquitin- and substrate-binding. Instead, it 
relies on the ubiquitin-interacting motif (UIM) in UBXN7 that directly engages the NEDD8 
modification on cullins. It leads to accumulation of HIF1α, a CUL2 substrate that uses 
UBXN7/VCP as a ubiquitin-receptor on its way to proteasome-mediated degradation.  
Also, HIF1α carrying long ubiquitin-chains can recruit alternative ubiquitin-receptors, 
lacking VCP's ATP-dependent segregase activity. Thus by sequestering CUL2 in its NEDD-
lated form, UBXN7 negatively regulates the ubiquitin-ligase activity of CRL2, and this 
might prevent recruitment of ubiquitin-receptors other than VCP to nuclear HIF1α 






 HBV integration into the human genome has been considered as one of the major 
causative factors to hepato-carcinogenesis. Analysis of in hepatocellular carcinoma 
tissues revealed that UBXN8 was significantly down-regulated, particularly the tissue with 
HBV integration within the intron of UBXN8. Further, the tumor suppressive activity of 
UBXN8 is dependent on a cell cycle negative regulator tumor protein 53 (TP53). Thus, 
UBXN8 is identified as a new tumor suppressor candidate (X. Li et al., 2014) . 
 Mouse UBXN8 expression was found to be highly tissue-specific and abundant in 
gonads. In testes, it is expressed in post-meiotic round spermatids, whereas in ovaries it is 
expressed in granulosa cells. UBXN8 associates directly with VCP via its UBX domain. It 
was shown that UBXN8 is a transmembrane protein that localizes to the ER membrane 
with its UBX domain facing the cytoplasm. Knock-down of UBXN8 expression in human 
cells leads to a decreased association of VCP with the ER membrane and concomitantly a 
slow degradation of misfolded ER-derived proteasome substrates. Thus, UBXN8 tethers 




 UBXN9 interact directly with VCP and also exhibit species, mutation and ATP-
dependent differences in the binding affinities. Also, UBXN9 efficiently disassembled wild-
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type, but to a lesser extent, mutant VCP hexamers into monomers (Rijal et al., 2016) . 
Another group found similar observations that UBXN9 promotes VCP hexamer 
disassembly, resulting in the formation of stable VCP-UBXN9 heterotetramers. An 
extended UBX domain (eUBX) in UBXN9 is critical for this association. The overproduction 
of UBXN9 disrupts VCP hexamer function in ERAD, and that engineered eUBX 
polypeptides can induce cell death, providing a rationale for developing anti-cancer 
polypeptide inhibitors that may target VCP activity (Arumughan et al., 2016) . 
 Alveolar soft part sarcoma (ASPS) is a rare tumor. In a study, UBXN9 -TFE3 fusion 
transcripts were observed in all 12 ASPS case and determined as its oncogenic significant 
fusion product.  The UBXN9-TFE3 fusion replaces the N-terminal portion of TFE3 by the 
fused UBXN9 sequences while retaining the TFE3 DNA-binding domain, implicating 




 UBXN10 localizes to cilia in a VCP-dependent manner, and both VCP and UBXN10 
are required for ciliogenesis. Pharmacological inhibition of VCP destabilized the 
intraflagellar transport B (IFT-B) complex and increased trafficking rates. Depletion of 
UBXN10 in zebrafish embryos causes defects in left-right asymmetry, which depends on 






 UBXN11/ Colon antigen-1 (COA-1) was recently identified as a novel antigen of 
colorectal cancer encoded by the UBXD5 gene. UBXN11-specific and tumor-reactive T 
lymphocytes were isolated from all studied colorectal cancer patients with the 
progressive disease but not in patients with early-stage tumor and healthy donors, 
suggesting that the immune response against this antigen is associated with the 
progression of colorectal cancer. UBXN11- and tumor-specific T lymphocytes displayed a 
CD3+CD4+CD69+CD45RA+ phenotype, compatible with the activated effector-type T-cell 
subset, and most of them exerted cytotoxic activity against HLA-matched and UBXN11+ 
tumor cells. UBXN11-specific T cells could also be isolated by in vitro stimulation of 
peripheral blood mononuclear cells with autologous dendritic cells loaded with tumor 
lysate, suggesting that this antigen can generate a dominant immunologic response 
against colorectal cancer cells. Notably, UBXN11-derived epitopes binding to HLA-A*0201 
molecules elicited antigen- and tumor-specific CD8+ T-cell-mediated responses in 




 p47 is a cofactor of VCP, and it is the best-studied UBXN. In the animal cells, p47 is 
required to be associated with VCP for budding of cisternae from mitotic Golgi fragments. 
In budding yeast cells, it is essential or the process called karyogamy/ outer membrane 
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fusion reaction (Kondo et al., 1997) . The p47 phosphorylation on Serine-140 by Cdc2 





Figure 8: Types of UBXNs and its domains. 
UBXNa are primarily divided into two groups depending on their domain. The first group 
consists of UBA-UBX domain-containing proteins and the second group consists of only 
UBX domain-containing proteins As adapted from (Alexandru et al., 2008)   
46 
 





































Interference of RIG-I signaling 
Negatively regulate NF-κB 
signaling 
Interact with Nipah virus V 
protein and interfere with 
IFN-β induction 
Negatively regulate ERAD 
 
EGFR activates NF-κB via 
negatively downregulating 
UBXN1, role in glioblastoma 
Negatively regulate BRACA1 
enzymatic action 
(P. Wang et al., 2013)  
(Y. B. Wang et al., 
2015)  




Bretscher, 2011)  
(Huang et al., 2017)  
 
 
(Wu-Baer et al., 
2010)  
UBXN2A UBXD4 29 UBX Promote cell death in colon 
cancer 
Regulation of nicotinic  
acetylcholine receptor 
(Sane et al., 2014)  
 
(Rezvani et al., 2009)  
UBXN2B NSFL1. 
cofactor3
37 UBX Membrane fusion 
 















(Ryu et al., 2003)  
 
(Xie et al., 2017)  







Lipid metabolism regulation 
Positive regulator of STING 
mediated antiviral immune 
response 
(Imai et al., 2015)  










50 UBX Lysosome clearance by 
autophagy 





(Papadopoulos et al., 
2017)  
(Ritz et al., 2011)  
(Haines et al., 2012)  












30 UBX Tumor suppressor 
ERAD 
(X. Li et al., 2014)  




60 UBX Monomerization of VCP 
hexamer 
 
TEF3 fusion in ASPS 
(Rijal et al., 2016)  
(Arumughan et al., 
2016)  
(Ladanyi et al., 2001)  




















2.1.1 Cell lines 
 
 Human embryonic kidney 293 cells transformed with T antigen of SV40 (HEK293T, 
# CRL-3216), Vero cells (monkey kidney epithelial cells, # CCL-81) were purchased from 
American Type Culture Collection (ATCC) (Manassas, VA20110, USA). A 2fGTH cell line 
stably expressed an ISRE-luciferase reporter. It was used previously (Jinzhu Ma et al., 
2018a) . HEK293T, Vero cells, and 2fGTH cells were grown in DMEM and trophoblast were 
grown in RPMI 1640 (Gibco) supplemented with 10% FBS, glutamine, antibiotics, and 




 Encephalomyocarditis virus (EMCV, VR129-B) and Zika virus FLR strain (Cat# VR-
1844) were purchased from American Type Culture Collection (ATCC) (Manassas, 
VA20110 USA). The Indiana strain of VSV was tagged with Green fluorescence protein 




2.1.3 Plasmid construction 
 
 FLAG-Myc-UBXN2A (Cat # MR203340), -2B (Cat# MR204884) were purchased from 
Origene (Rockville, MD 20850, USA). FLAG-UBXN1 was constructed previously in our lab. 
The additional FLAG-UBXNs (which include FLAG-UBXN3A, FLAG-UBXN3B, FLAG-UBXN4, 
FLAG-UBXN6, FLAG-UBXN7, FLAG-UBXN8, FLAG-UBXN9, FLAG-UBXN10, FLAG-UBXN11, 
P47) were a kind gift of Dr. Raymond J. Deshaies at California Institute of Technology, 
USA. 
 
2.1.4 Ligand treatment conditions 
 
 PRR ligand 100 ng of RIG-I plasmid or 4 μg/ml poly (I: C) (Invivogen #tlrI-pic) were 
transfected into cells with Lipofectamine 2000.  Human IFN-β (PeroTech #300-02BC-5UG) 
or human IFN-λ1 (PeroTech #300-02L-5UG) were added to the growth medium without 
serum at the final concentration of 10ng/ml of medium. The cells were incubated for 0, 
30, 60 minutes following treatment, for the determination of JAK-STAT molecules. The 
incubation was for 16-24hrs for determining the ISG mRNA levels after stimulation.   
 
2.1.5 Lipofectamine transfection protocol 
 
  24 well plate seeded with 50,000 HEK-293T cells/well and incubated at 370 C with 
5% CO2. After 16-24 hrs, cells were 50-80% confluent. The cell culture medium was 
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changed to serum-free DMEM. Plasmids with required concentration were added to 
serum-free DMEM in 1.5 ml microcentrifuge tube. In another 1.5 ml microcentrifuge 
tube, Lipofectamine 2000 reagent was added to serum-free DMEM. Both mixtures were 
incubated for 5 minutes separately and then added and incubated for 20 minutes at room 
temperature.  The prepared DNA + Lipofectamine 2000 transfection mix was added to 
cells in a dropwise manner. Cells were incubated at 370C with 5% CO2. After 6-10 hours, 
the culture medium was changed to DMEM with 10% serum. 
 
2.1.6 Virus infection conditions 
 
 The viruses were allowed to infect cells for two hours in the serum-free medium; 
the cells were then washed with 1× phosphate-buffered saline (PBS) once and incubated 
with pre-warmed medium with 10% serum. The MOI and infection conditions were 





2.2.1 Dual-Luciferase reporter assay 
2.2.1.1 Rationale 
 
 Dual Luciferase reporter system is developed to measure renilla and firefly 
luciferase activity in the same sample (Figure 9) (Grentzmann et al., 1998) . Firefly 
luciferase is a 61kDa and Renilla luciferase a 36kDa protein. Both are monomeric, and 
neither requires post-translational processing so that they can function as genetic 
reporters immediately upon translation.  
 The activity of the primary reporter gene is proportional to the specific treatment, 
while the control reporter gene provides internal control to normalize results. The 
advantage of dual glow system is the establishment of the internal control, which reduce 
sample variation by reducing false negative or false positive readouts caused by non-





Figure 9:  The principle of a dual nonsecreted luciferase reporter assay. 
Transfection of two reporter plasmid vectors consist of the firefly luciferase gene 
sequence downstream to target promoter (ISRE in our system), and the Renilla luciferase 
gene sequence with the constitutive promoter sequence as a control. The promoter 
region regulates the expression of the luciferase genes in living cells. Firefly luciferase 
protein catalyzes the externally provided substrate luciferin in the presence of Mg2+ and 
ATP to produce a yellow-green light. This reaction is stopped by the inhibitor, and 
subsequent renilla luciferase activity is measured as proportional to the production of 





 24 well plate seeded with 50,000 HEK-293T cells/well. After 16-24 hrs, 50-80% 
confluent HEK293T cells were transfected with Calcium phosphate transfection method. 
Briefly, a combination of 3 plasmids including 100 ng of pGL3-ISRE luciferase reporter 
(firefly luciferase; experimental reporter) plasmid, 10ng of Actin-Renilla reporter (renilla 
luciferase; internal control), and each UBXN expressing plasmid are mixed with 100µL 
0.25M CaCl2 and incubated at room temperature for 15 minutes. Then 100µL 2xHBS 
added dropwise with aeration. They were incubated at room temperature for 20 minutes. 
200µL of plasmid- Calcium phosphate Complex is added to each well. After 10-12 hours 
10ng/mL hIFNβ or hIFNλ was added. 16 hrs after transfection, luciferase activity was 
measured using a Promega Dual- Glow Luciferase assay system (Cat# E2920).  
 Briefly, media were removed from multiwell plates. Cells were washed with 500 
µL cooled 1X PBS and lysed by adding 50 µL of 1X passive lysis buffer to each well. To 5 µL 
of cell lysate is aliquoted to 1.5 mL microcentrifuge tube, 30 µL Dual-Glo Luciferase 
Reagent was added, and firefly luciferase activity was measured in terms of luminescence 
produced by a luminometer. To the same sample, 30 µL STOP-Glo Luciferase Reagent was 
added and mixed, and Renilla luciferase activity was measured in terms of luminescence 
produced by a luminometer.  
 




 The luminescence values and the ratio of luminescence from the ISRE reporter to 
luminescence from the control Renilla reporter were noted. This ratio was normalized to 
the ratio of a control well of non-stimulated vector control. Relative Response Ratios was 
calculated from IFN stimulated Vector samples to the IFN stimulated UBXNs samples.  
 
2.2.2 Biochemical Assay for IFN-I bioavailability 
 
 IFN-I concentration in the cell culture supernatant was measured by 2fGTH 
reporter cell line. This cell line stably expresses the ISRE-luciferase reporter, which is 
activated in proportion to IFN concentration (Jinzhu Ma et al., 2018a) . Briefly, 1 × 
105 2fGTH cells were seeded in each well of 24-well plate and grown in complete DMEM 
supplemented with 10% FBS and antibiotics/antimycotics at 37°C, 5% CO2overnight. Two 
hundred microliters of samples of pre-stimulated HEK293T culture medium were added 
to the 2fGTH-ISRE-Luc cells and incubated at 37°C, 5% CO2 for ten hours. A serial two-fold 
dilution of recombinant human IFN-β served as positive controls and was used for a 
standard curve plot. Unstimulated HEK293T cell culture medium served as a negative 






2.2.3 Generation of gene knockout cell lines with CRISPR-Cas9 technology  
2.2.3.1 Background 
 
 CRISPR technology was used to generate knockout cells (Figure 10). We co-
expressed an endonuclease- Cas9 and a guide RNA (gRNA) specific to the UBXN6 gene 
exon2 sequence. The 20 nucleotide DNA sequence of the target was chosen based on two 
characteristics: 
1. The target sequence was unique compared to the rest of the genome. 
2. A Protospacer Adjacent Motif (PAM)/ NGG sequence was present immediately 






Figure 10: The mechanism of CRISPR-Cas9 technology. 
The expressed Cas9 protein and gRNA form a ribonucleoprotein complex through 
interactions between the gRNA scaffold and surface-exposed positively-charged grooves 
on Cas9. The Cas9 + gRNA complex undergoes a conformational change, in which the 
active Cas9 bind to DNA, whereas the spacer region of the gRNA, remains free to interact 
with target DNA. The Cas9 nuclease has two functional endonuclease domains: RuvC and 
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HNH. Cas9 undergoes a second conformational change upon target binding that positions 
the nuclease domains to cleave opposite strands of the target DNA. The result of Cas9-
mediated DNA cleavage is a double-strand break (DSB) within the target DNA (∼3-4 
nucleotides upstream of the PAM sequence). The resulting DSB is then repaired by one of 
two general repair pathways: 
1. The efficient but error-prone non-homologous end joining (NHEJ) pathway 
2. The less efficient but high-fidelity homology-directed repair (HDR) pathway 
The NHEJ repair pathway is the most effective repair mechanism, and it frequently causes 
small nucleotide insertions or deletions (indels) at the DSB site. The randomness of NHEJ-
mediated DSB repair has important practical implications because a population of cells 
expressing Cas9 and a gRNA will result in a diverse array of mutations. 
In most cases, NHEJ gives rise to small indels in the target DNA that result in amino acid 
deletions, insertions, or frameshift mutations leading to premature stop codons within 
the open reading frame (ORF) of the targeted gene. The typical result is a loss-of-function 







 Well established CRISPR-Cas9 protocol was used to create gene knockout (Figure 
11) (Ran et al., 2013)  
 
2.2.3.2.1 Designing gRNA: 
 The 20 nucleotides long gRNA specific to the UBXN6 gene exon2 sequence were 
designed based on the unique target sequence and PAM/ NGG sequence adjacent to 





Table 2: Two sequences of human UBXN6 gene at exon-2 were targeted by designing a 
pair of gRNA. 
 
Gene gRNA Primer sequence 
UBXN6_CRISPR-F1 CAC CGT CGG ATG GTG TCC TGC GAT G 
UBXN6_CRISPR-R1 AAA CCA TCG CAG GAC ACC ATC CGA C 
UBXN6_CRISPR-F2 CAC CGG CTG GTT GGG CTT CTC TTT G 







 The primer pairs were annealed and cloned into Lenti-CRISPR V2 plasmid 
separately (Sanjana et al., 2014) . The cloned g-RNA was confirmed by sequencing using 
the LKO.1 primer with the sequence 5'-GAC TAT CAT ATG CTT ACC GT-3.'  
 
2.2.3.2.3 Production of packaging Lentivirus particles: 
 
 The g-RNA- Lenti-CRISPR V2 vector was co-transfected into HEK293T cells with the 
packaging plasmids pCMV-VSV-G (Addgene# 8545) and psPAX2 (Addgene# 12260) in ratio 
1:2:2. The first harvest of supernatant Lentivirus particles was collected after two days of 
transfection. The second harvest was after 4 days of transfection. The medium was 
centrifuged, and the supernatant was stored at -80o C. 
 
2.2.3.2.4 Transduction and selection of knock-out clone: 
 
 HEK293Tcells, trophoblasts were then transduced by lentiviral particles for three 
days. The efficiency of transduction was increased by adding polybrene. The wild type 
(WT) control was lentiCRISPRv2 vector only. The puromycin (1 μg/ml) selection applied to 
transduced cells for both HEK293T cells and trophoblasts. The non-transduced cells died 
of puromycin, while all transduced cells were survived. Immunoblotting confirmed the 
successful knockout clones. For RT-PCR, the primer pair to find the gene deletion was 
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designed which target the selected sgRNA sequence and the sequence 100 nucleotides 




Table 3: The designing of primer pairs for detection of UBXN6 deletion by qPCR. 
Gene Primer sequence 
UBXN6-QPCR1-FWD AGG CCC ACA AAG AGA AGC 
UBXN6-QPCR1-REV TGG GGC CCC AGG CCC GGG 
UBXN6-QPCR2-FWD GGC CCC ACA TCG CAG GAC 







Figure 11: Protocol for the generation of gene knockout by CRISPR technology. 
Briefly, the target-specific gRNA was designed and cloned into Lenti-CRISPR V2 plasmids. 
The CRISPR-Cas9 + gRNA library was amplified and packaged into lentivirus particle and 
used to transduce target cells. The transduced cells were selected by puromycin survival. 
The knockout of the target gene was confirmed by immunoblotting As adapted from 





2.2.4 Reverse transcription and quantitative PCR (qPCR) 
 
 The cells were washed with 1X PBS and lysed in 350μl of RLT buffer containing β-
mercaptoethanol (QIAGEN RNeasy mini kit). The total RNA was extracted following the 
QIAGEN RNeasy manufacturer’s instructions. Reverse-transcription of RNA into cDNA was 
performed using the BIO-RAD iScript cDNA Synthesis Kit. qPCR was performed with gene-
specific primers and SYBR Green. Results were calculated using the –ΔΔCt method and a 
housekeeping gene as an internal control. The qPCR primers were listed in the Previous 
study (Yang et al., 2018) .  The housekeeping gene controls were beta-actin (ACTB). These 
primer sequences are listed (Table 4). 
 Fold induction was the change in gene expression after infection or stimulation. It 
was calculated as the ratio of induced (infected/stimulated) to basal (non-




Table 4: The primers used for detection of gene expression by qPCR. 
 













hIFNB -F CAGCAATTTTCAGTGTCAGAAGCT 













2.2.5 PCR array of human IFN-I Response  
 
 Isolated RNA was reverse transcribed using a cDNA kit. The cDNA was used on the 
real-time RT Profiler PCR Array (Table 5) (QIAGEN, Cat. no. PAHS-016Z) in combination 
with SYBR Green qPCR Mastermix (Cat. no. 330529). CT values were exported to an Excel 
file to create a table of CT values. This table was then uploaded on to the data analysis 
web portal at http://www.qiagen.com/geneglobe. Samples were assigned to controls and 
test groups. CT values were normalized based on a/an Automatic selection from HKG 
panel of reference genes. 
 The data analysis web portal was used to calculate the fold change/regulation by 
the delta-delta CT method. Briefly, delta CT is calculated between the gene of interest 
(GOI) and an average of reference genes (HKG), followed by delta-delta CT calculations 
(delta CT (Test Group)-delta CT (Control Group)). Fold Change is then calculated using two 
^ (-delta delta CT) formula. The data analysis web portal also plots scatter plot, volcano 
plot, clustergram, and heat map. This data analysis report was exported from the QIAGEN 




Table 5: The design of the PCR array plate for human IFN-I response gene. 
     Posi
tion Unigene Refseq Symbol Description 
A01 Hs.12341 NM_001111 ADAR Adenosine deaminase, RNA-specific 
A02 Hs.523309 NM_004281 BAG3 BCL2-associated athanogene 3 
A03 Hs.118110 NM_004335 BST2 Bone marrow stromal cell antigen 2 
A04 Hs.2490 NM_033292 CASP1 
Caspase 1, apoptosis-related cysteine 
peptidase (interleukin 1, beta, convertase) 
A05 Hs.74034 NM_001753 CAV1 Caveolin 1, caveolae protein, 22kDa 
A06 Hs.303649 NM_002982 CCL2 Chemokine (C-C motif) ligand 2 
A07 Hs.514821 NM_002985 CCL5 Chemokine (C-C motif) ligand 5 
A08 Hs.501497 NM_001252 CD70 CD70 molecule 
A09 Hs.838 NM_005191 CD80 CD80 molecule 
A10 Hs.171182 NM_006889 CD86 CD86 molecule 
A11 Hs.238990 NM_004064 CDKN1B 
Cyclin-dependent kinase inhibitor 1B (p27, 
Kip1) 
A12 Hs.701991 NM_000246 CIITA 
Class II, major histocompatibility complex, 
transactivator 
B01 Hs.709456 NM_000567 CRP C-reactive protein, pentraxin-related 
B02 Hs.632586 NM_001565 CXCL10 Chemokine (C-X-C motif) ligand 10 
B03 Hs.190622 NM_014314 DDX58 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 
B04 Hs.131431 NM_002759 EIF2AK2 
Eukaryotic translation initiation factor 2-
alpha kinase 2 
B05 Hs.62661 NM_002053 GBP1 
Guanylate binding protein 1, interferon-
inducible 
B06 Hs.181244 NM_002116 HLA-A Major histocompatibility complex, class I, A 
B07 Hs.77961 NM_005514 HLA-B Major histocompatibility complex, class I, B 
B08 Hs.650174 NM_005516 HLA-E Major histocompatibility complex, class I, E 
B09 Hs.512152 NM_002127 HLA-G Major histocompatibility complex, class I, G 
B10 Hs.380250 NM_005531 IFI16 Interferon, gamma-inducible protein 16 
B11 Hs.532634 NM_005532 IFI27 Interferon, alpha-inducible protein 27 
B12 Hs.14623 NM_006332 IFI30 Interferon, gamma-inducible protein 30 
C01 Hs.730125 NM_002038 IFI6 Interferon, alpha-inducible protein 6 
C02 Hs.163173 NM_022168 IFIH1 Interferon induced with helicase C domain 1 
C03 Hs.20315 NM_001548 IFIT1 
Interferon-induced protein with 
tetratricopeptide repeats 1 
C04 Hs.437609 NM_001547 IFIT2 
Interferon-induced protein with 
tetratricopeptide repeats 2 
C05 Hs.47338 NM_001549 IFIT3 
Interferon-induced protein with 
tetratricopeptide repeats 3 
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C06 Hs.458414 NM_003641 IFITM1 
Interferon induced transmembrane protein 
1 (9-27) 
C07 Hs.709321 NM_006435 IFITM2 
Interferon induced transmembrane protein 
2 (1-8D) 
C08 Hs.374650 NM_021034 IFITM3 
Interferon induced transmembrane protein 
3 
C09 Hs.37026 NM_024013 IFNA1 Interferon, alpha 1 
C10 Hs.211575 NM_000605 IFNA2 Interferon, alpha 2 
C11 Hs.1510 NM_021068 IFNA4 Interferon, alpha 4 
C12 Hs.529400 NM_000629 IFNAR1 
Interferon (alpha, beta and omega) receptor 
1 
D01 Hs.708195 NM_000874 IFNAR2 
Interferon (alpha, beta and omega) receptor 
2 
D02 Hs.93177 NM_002176 IFNB1 Interferon, beta 1, fibroblast 
D03 Hs.682604 NM_176891 IFNE Interferon, epsilon 
D04 Hs.73010 NM_002177 IFNW1 Interferon, omega 1 
D05 Hs.193717 NM_000572 IL10 Interleukin 10 
D06 Hs.168132 NM_000585 IL15 Interleukin 15 
D07 Hs.654458 NM_000600 IL6 Interleukin 6 (interferon, beta 2) 
D08 Hs.436061 NM_002198 IRF1 Interferon regulatory factor 1 
D09 Hs.654566 NM_002199 IRF2 Interferon regulatory factor 2 
D10 Hs.289052 NM_001571 IRF3 Interferon regulatory factor 3 
D11 Hs.521181 
NM_001098
629 IRF5 Interferon regulatory factor 5 
D12 Hs.166120 NM_001572 IRF7 Interferon regulatory factor 7 
E01 Hs.1706 NM_006084 IRF9 Interferon regulatory factor 9 
E02 Hs.458485 NM_005101 ISG15 ISG15 ubiquitin-like modifier 
E03 Hs.459265 NM_002201 ISG20 
Interferon stimulated exonuclease gene 
20kDa 
E04 Hs.207538 NM_002227 JAK1 Janus kinase 1 
E05 Hs.656213 NM_004972 JAK2 Janus kinase 2 
E06 Hs.80395 NM_002371 MAL Mal, T-cell differentiation protein 
E07 Hs.132966 NM_000245 MET 
Met proto-oncogene (hepatocyte growth 
factor receptor) 
E08 Hs.153837 NM_002432 MNDA Myeloid cell nuclear differentiation antigen 
E09 Hs.517307 NM_002462 MX1 
Myxovirus (influenza virus) resistance 1, 
interferon-inducible protein p78 (mouse) 
E10 Hs.926 NM_002463 MX2 
Myxovirus (influenza virus) resistance 2 
(mouse) 
E11 Hs.82116 NM_002468 MYD88 
Myeloid differentiation primary response 
gene (88) 
E12 Hs.54483 NM_004688 NMI N-myc (and STAT) interactor 
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F01 Hs.709191 NM_000625 NOS2 Nitric oxide synthase 2, inducible 
F02 Hs.524760 NM_002534 OAS1 2'-5'-oligoadenylate synthetase 1, 40/46kDa 
F03 Hs.414332 NM_002535 OAS2 2'-5'-oligoadenylate synthetase 2, 69/71kDa 
F04 Hs.654583 NM_033238 PML Promyelocytic leukemia 
F05 Hs.496255 NM_002744 PRKCZ Protein kinase C, zeta 
F06 Hs.375217 NM_002818 PSME2 
Proteasome (prosome, macropain) activator 
subunit 2 (PA28 beta) 
F07 Hs.349094 NM_002351 SH2D1A SH2 domain containing 1A 
F08 Hs.521482 NM_003028 SHB 
Src homology 2 domain containing adaptor 
protein B 
F09 Hs.50640 NM_003745 SOCS1 Suppressor of cytokine signaling 1 
F10 Hs.642990 NM_007315 STAT1 
Signal transducer and activator of 
transcription 1, 91kDa 
F11 Hs.530595 NM_005419 STAT2 
Signal transducer and activator of 
transcription 2, 113kDa 
F12 Hs.463059 NM_003150 STAT3 
Signal transducer and activator of 
transcription 3 (acute-phase response 
factor) 
G01 Hs.731555 NM_000593 TAP1 
Transporter 1, ATP-binding cassette, sub-
family B (MDR/TAP) 
G02 Hs.29344 NM_182919 TICAM1 Toll-like receptor adaptor molecule 1 
G03 Hs.522632 NM_003254 TIMP1 TIMP metallopeptidase inhibitor 1 
G04 Hs.657724 NM_003265 TLR3 Toll-like receptor 3 
G05 Hs.659215 NM_016562 TLR7 Toll-like receptor 7 
G06 Hs.660543 NM_138636 TLR8 Toll-like receptor 8 
G07 Hs.87968 NM_017442 TLR9 Toll-like receptor 9 
G08 Hs.379754 NM_198282 
TMEM1
73 Transmembrane protein 173 
G09 Hs.478275 NM_003810 TNFSF10 
Tumor necrosis factor (ligand) superfamily, 
member 10 
G10 Hs.510528 NM_003300 TRAF3 TNF receptor-associated factor 3 
G11 Hs.75516 NM_003331 TYK2 Tyrosine kinase 2 
G12 Hs.73793 NM_003376 VEGFA Vascular endothelial growth factor A 
H01 Hs.520640 NM_001101 ACTB Actin, beta 
H02 Hs.534255 NM_004048 B2M Beta-2-microglobulin 
H03 Hs.592355 NM_002046 GAPDH 
Glyceraldehyde-3-phosphate 
dehydrogenase 
H04 Hs.412707 NM_000194 HPRT1 Hypoxanthine phosphoribosyltransferase 1 
H05 Hs.546285 NM_001002 RPLP0 Ribosomal protein, large, P0 
H06 N/A SA_00105 HGDC Human Genomic DNA Contamination 
H07 N/A SA_00104 RTC Reverse Transcription Control 
H08 N/A SA_00104 RTC Reverse Transcription Control 
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H09 N/A SA_00104 RTC Reverse Transcription Control 
H10 N/A SA_00103 PPC Positive PCR Control 
H11 N/A SA_00103 PPC Positive PCR Control 





2.2.6 ELISA (enzyme-linked immunosorbent assay) 
 
  A commercial ELISA kit was used to measure the interferon levels in the cell 
culture supernatants. The levels of IFN-λ2 (Cat # RHF333CK) and IFN-β (Cat# RHF842CK, 
from Antigenix America, INC) were quantified. Briefly, the plate was prepared by adding 
100 uL of the diluted capture antibody with 0.05M Carbonate buffer (or PBS) to 
concentration 1.0 ug/mL. The plate was sealed and incubated overnight at room 
temperature. All liquid was removed, and plates were washed four times using 300 uL of 
wash buffer per well. After last wash, 200 uL ANTIGENIX AMERICA ELISA coating stabilizer 
cat # EA150) was added and incubated for 60 minutes at room temperature. The standard 
was serially diluted from 10.0 ng/mL to zero, and 100 uL of standard or undiluted samples 
were added to each well in triplicate and incubated at room temperature for 2 hours. The 
plate was aspirated and washed four times. 100 uL per well detection (Biotin Tracer) 
antibody in the diluent to the concentration of 0.20 ug/mL was added and incubated at 
room temperature for 1 hour. The plate was aspirated and washed four times. 100 uL per 
well Streptavidin-HRP conjugate 1:1,000 in diluent was added and incubated for 30 
minutes at room temperature. The plate was aspirated and washed four times. 100 uL 
per well substrate solution was added and incubated for 10 minutes at room 
temperature. 100 uL stop solution was added to stop color development. The plate was 







 Samples were prepared from cultured cells after washing with ice-cold 1X PBS. 
Cold Triton lysis buffer was added to well/ plate/ flask. Lysates were kept on ice with 
constant agitation for 30 minutes. The microcentrifuge tubes containing lysates were 
centrifuged at 12,000 rpm for 20 minutes at 4oC. The supernatant was transferred to a 
new tube, mixed with SDS loading dye with freshly added β-mercaptoethanol and used 
for electrophoresis. Equal amounts of protein were loaded into the wells of the SDS-
PAGE gel, along with molecular weight marker. The gel was run for 1–2 h at 100 V. Next, 
the proteins were transferred from gel to nitrocellulose membrane by wet transfer 
method. The membrane was washed and blocked for one h at room temperature in the 
1% milk as blocking buffer. The membrane was incubated with appropriate dilutions of 
primary antibody in blocking buffer overnight at 4°C (Table 6). The membrane was 
washed three times in TBST 10 min each and incubated with the recommended in HRP-
conjugated secondary antibody in blocking buffer at room temperature for one h. An 
enhanced chemiluminescent (ECL) substrate (ThermoFisher Cat# 32106) was applied, and 









wt(kDa) Dilution Source Catalog number 
Flag (1mg/ml)     1-1000 mouse collaborator 
GAPDH 
(1mg/ml) H M R 36  
0.1-
0.2µg/ml rabbit sigma G9545 
Tubulin(DM1A) H M R Mk 52 1-1000 mouse 
Cell signal 
3873ing 






Stat1(Tyr701) H M 84, 91 1-1000 rabbit 
Cell Signaling 
9167 










 ANTI-FLAG M2 Magnetic Beads (Sigma # M8823) is composed of the ANTI-FLAG 
M2 monoclonal antibody attached to superparamagnetic iron impregnated, 4% agarose 
beads. The M2 antibody binds to fusion proteins containing the FLAG peptide sequence 
(Brizzard et al., 1994) . Additionally, the M2 antibody recognizes the FLAG octapeptide 
sequence (N-Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys-C) at the N-terminus, Met-N-terminus, or 
C-terminus locations of a fusion protein in mammalian and bacterial extracts. Hence, they 
are used to detect and capture of fusion proteins containing a FLAG peptide sequence by 
commonly used immunoprecipitation procedures (Safarik and Safarikova, 2004) .  
 
2.2.8.2 Sample Preparation: 
 
 1x107 HEK293T cells were transfected with either empty vector or expression 
plasmids (FLAG-UBXN6) using Lipofectamine 2000. After 24 hours, transfected cells were 
treated with human IFN-β (10ng/ml) for 60 minutes. The four experiemental groups were: 
1. IP1-Vector control 
2. IP2-Vector + IFNλ 
3. IP3- FLAG-UBXN6 
4. IP4- FLAG-UBXN6 + IFNλ 
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Whole cell lysates were prepared from transfected cells in 1ooµl lysis buffer. The lysates 
were cleared by centrifugation at 10,000g for 20min at 4°C. Whole cell lysates were 




 The resin was thoroughly resuspended and transferred to a microcentrifuge tube. 
The beads were equilibrated by resuspending with five packed gel volumes of TBS (50 
mM Tris HCl, 150 mM NaCl, pH 7.4) for five times. The cleared lysates were incubated 
with the Beads with gentle agitation at 4°C overnight. Once the binding step was 
complete, the magnetic beads were collected by placing the tube in the appropriate 
magnetic separator (Promega # Z5434) and removed the supernatant. The resin beads 
were washed with TBS buffer to remove all of the nonspecifically bound proteins. The 
beads were washed five times in ice-cold 1X wash buffer. The bound proteins were eluted 
by competition with the FLAG Peptide by adding five packed gel volumes of a solution 
containing the 3X- FLAG peptide (Sigma# F 4799) in TBS buffer. The supernatants were 
incubated with gentle shaking on a rotator for 30 minutes at room temperature. The 
supernatants were collected by placing the tubes in the magnetic separator. The 
supernatants were stored at -20o C, used for SDS-PAGE analysis with Coomassie blue 
staining and sent for Mass spectrometry evaluation at the Proteomics and Metabolomics 
facility, University of Connecticut, Storrs, Connecticut. 
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 A Thermo Q Exactive HF Orbitrap mass spectrometer coupled to a Dionex Ultimate 
RSLCnano UPLC was used for the analysis at the Proteomics and Metabolomics facility, 
University of Connecticut, Storrs, Connecticut. All data was processed with the MaxQuant 
search algorithm and visualized with Scaffold Q+S.  
  
2.2.8.4 Data analysis of Mass Spectrometry: 
 
 The results obtained from the Mass spectrometry evaluation identified total 522 
proteins in four IP samples; denoted with their name, accession number, alternate ID, 
molecular weight, protein grouping ambiguity and total spectrum count of each group. 
 A spectrum count is a single MS/MS spectrum that has been matched to a single 
peptide sequence from any given identified protein. The acquisition method samples the 
most abundant peptide ions first, so spectral counts are a rough estimate of overall 
protein abundance (most abundant proteins will have the highest number of spectral 
counts), with a few caveats. 
  The first fifty proteins, which shows highest total spectrum count were tabulated. 
The total spectrum counts of bound proteins were normalized to input UBXN6 counts. 
Amongst the fifty identified proteins three UBXN6-interacting proteins with the highest 




2.2.9 Quantification of infectious viral particles by Plaque-forming assay 
 
 The 6-well plates were seeded with Vero cells in DMEM with 10% FBS, antibiotics 
and glutamine so that cells were 90% confluent on the day of the assay (2.5x105 
cells/well). The virus dilutions were made in DMEM without serum by making serial 10-
fold dilutions. The medium was changed to pre-warmed DMEM without serum. The 
100ul/well serial dilutions of the supernatant were added to confluent Vero cells in 
duplicates and incubated at 37 °C for two h. The inoculum was then replaced with warm 2 
ml of DMEM complete medium with 1% SeaPlaque agarose (Cat# 50100, Lonza). Plates 
were incubated at 37 °C, 5% CO2 and plaques were monitored under the microscope 
each day. The second overlay of Neutral red (Sigma-Aldrich) solution and agarose were 
added after incubation. Plaques were visualized as clear zones in red background. 
 
2.2.10 RNA Interference by siRNA 
 
 1 × 105 HEK293 were plated into polyornithine-coated 24-well cell culture plates. 
Sixteen hours later, cells were transfected with 40 pmol of siRNA mix directed against 
human UBXN6 (three 27-mer siRNAs from Origene) or scramble control, by Lipofectamine 
2000 (Invitrogen). Cells were transfected again with luciferase reporter plasmids (100 ng 
ISRE-Luc and ten ng Act-Renilla per well) 36 hr after siRNA transfection. Cells were 
transfected with ∆RIG-I plasmids 48 hr after siRNA transfection. Cells were washed gently 
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with PBS and lysed for Dual Glow Luciferase assay following the manufacturer’s 
instructions (Promega) 16 hr after infection.  
 
2.3 Graphing and statistics 
 
 Graph Pad Prism 7 software was used for graphs and statistical analyses. For all 
the graphs, data were expressed as mean ± s.e.m. A standard two-tailed unpaired 
Student’s t-test was calculated in Microsoft Excel.  
 P values ≤ 0.05 were considered significant and denoted with **, while P values ≤ 
0.01 were denoted with *. The sample sizes (biological replicates), specific statistical tests 
used, and the main effects of statistical analysis for each experiment were detailed in 






Aim 1: To identify a UBXN proteins that acts as a positive regulators of RNA virus-
induced innate immune responses. 
 
 Our previous studies characterized the role of UBXN1 in negative regulation of 
RNA virus-induced innate immune responses and a role of UBXN3B as a positive regulator 
of the innate immune response to DNA virus infections. Hence, in this project, we will 
screen all UBXNs to determine the positive regulator of RNA virus-induced immune 
responses.    
 
Sub-aim 1.1: To screen for the UBXN that positively regulates type I IFN responses. 
Sub-aim 1.2: To validate the UBXN screening for the role of UBXN6 in the regulation of 
IFN-stimulated responses. 
 





 The screening from Aim 1 suggests that UBXN6 positively regulates RNA virus-
induced IFN-I/III responses. To validate the results from the UBXN6 overexpression 
studies, we evaluated IFN-I/III expression and viral replication in UBXN6 deficient cells. 
Two approaches were undertaken for gene abrogation; gene knockdown by siRNA and 
gene knock out by CRISPR-Cas9 technology. We have established the protocol for the 
generation of knockout cells by CRISPR technology. The HEK293 and trophoblast 
knockout cells (indicated as UBXN6-/- hereafter) were used to explore the function of this 
gene in IFN-I/III responses and viral replication. 
 
Sub-aim 2.1: To determine the role of UBXN6 in host immune responses by siRNA 
knockdown of UBXN6. 
Sub-aim 2.2: To generate UBXN6 knockout in HEK293 and trophoblast cells by CRISPR-
Cas9 technology and to examine host immune responses as well as a viral infection in 
knockout cells. 
 
Aim 3: To find out the molecular mechanism by which UBXN6 resists viral infections and 
regulates the immune responses. 
 
 UBXN6 was shown to induce hIFN-β-, and hIFN-λ-stimulated ISRE promoter 
activity (from Aim 1-screen). This also indicates that the activity of Type I/III interferon-
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induced JAK/STAT signaling pathway is enhanced by UBXN6. Hence, we hypothesize that 
UBXN6 can regulate IFN- JAK-STAT signaling pathway. 
 
Sub-aim 3.1: To test if recombinant hIFN-λ-induced ISG response is deficient in UBXN6-/- 
cells. 






 The roles of UBXNs in the regulation of antiviral immune responses have not been 
much explored. Previous work in our lab identified UBXN1 as a negative regulator of the 
RLR pathway and UBXN3B as a positive regulator of STING-mediated immune responses. 
In this study, we aimed to determine the member of UBXNs as a positive regulator of RNA 
virus infection-induced innate immune responses. By using an ISRE-driven luciferase 
reporter assay that monitors the activity of type I/III IFN-induced JAK-STAT signaling, we 
identified that UBXN6 overexpression synergized with RIG-I, IFN-β or IFN-λ to enhance 
antiviral immune responses. We further used siRNA and CRISPR-Cas9 technology to 
abrogate UBXN6 function, which was used to establish the function of UBXN6 in viral 
infection and JAK-STAT signaling. By PCR array we found that UBXN6-deficiency led to a 
reduction in type I/III IFN-induced gene expression, which was validated by qPCR. Also, 
RNA virus replication was increased in UBXN6-deficient when compared to UBXN6-
sufficient cells, which was accompanied by a significant reduction in IFN-β and IFN-λ.  
Lastly, we decoded the mechanism by which UBXN6 regulates the JAK-STAT pathway. We 
observed that IFN-β-stimulated STAT1 phosphorylation was impaired in UBXN6-deficient 
cells. By co-immunoprecipitation techniques and mass spectrometry analysis, we 
identified that following IFN-β stimulation UBXN6 interacted with PRMT5, a protein 
methyl transferase known to modify and interact with JAK1/2. Our results demonstrate 




4.1 Aim 1: To identify a member of UBXN proteins as a positive regulator of 
RNA virus-induced innate immune responses. 
 
 Our previous studies characterized the role of UBXN1 in negative regulation of 
RNA virus-induced innate immune responses and a role of UBXN3B as a positive regulator 
of the innate immune response to DNA virus infections. Hence, in this project, we will 
screen all UBXNs to determine the positive regulator of RNA virus-induced immune 
responses.    
 
4.1.1.1 Sub-aim 1.1: To screen for the UBXN that positively regulates type I IFN 
responses. 
 
We performed a screening in human embryonic kidney 293 cells transformed with 
T antigen of SV40 (HEK293T) cells for UBXNs that enhanced ∆RIG-I-stimulated ISRE 
reporter activity. ∆RIG-I is the 2CARD domain open conformation of RIG-I. It is 
constitutively active.  ∆RIG-I stimulated a robust ISRE activity in vector control and UBXN6 
enhanced ISRE by ~2 times compared to the treated vector control. UBXN6 was the only 
UBXN that potentiated the RIG-I-induced interferon effect (Figure 12). Next, we screened 
the anti-RNA virus activity of all known UBXNs using VSV as a model RNA virus, which 
specifically stimulate RIG-I signaling. Amongst all tested UBXNs, overexpression of UBXN6 
repressed VSV replication most dramatically as identified by Western blotting of VSV-G 




Figure 12: Ectopic expression of UBXN6 enhances RIG-I- induced IFN-I response.  
(A) Quantification of ISRE promoter activities by a Dual-Luciferase assay in HEK293T cells 
transfected with either 100ng of vector or 100ng of individual FLAG-UBXN plasmids together with 
reporter plasmids 16hr after ∆RIG-I transfection.  
The immunoblot of whole cell lysates depicts the expression levels of FLAG-UBXN proteins, and α-
Tubulin serves as a housekeeping protein control.  
Data represent the mean ± SEM (n = 3), Student’s t-Test:  two tailed distribution, two-sample 












































Figure 13:  Immunoblot of VSV-G in the whole cell lysates prepared from HEK293T cells.  
Cells were transfected with either vector or individual FLAG-UBXN plasmid and infected with VSV-




































































4.1.1.2 Sub-aim 1.2: To validate the UBXN screening for the role of UBXN6 in the 
regulation of IFN stimulated responses. 
 
The primary immune response in the innate immunity is characterized by viral 
RNA recognition by RLRs. This recognition is transduced downstream to generate IFN-
I/IIIs. The secreted IFN-I/IIIs further act on IFN receptor-bearing cells to activate JAK-STAT 
signaling, which stimulates several hundreds of ISGs to interfere with viral processes 
directly and also augmentIFN-I/III production. The activation of primary IFN-I and 
secondary JAK-STAT pathways was measured by total ISRE activity. Hence, we performed 
another screening in human embryonic kidney 293 cells transformed with T antigen of 
SV40 (HEK293T) cells for UBXNs that enhanced type I/III IFN- stimulated response 
element (ISRE) reporter activity. We observed that expression of UBXN6 increased basal 
ISRE by ~2.5 times compared to the empty vector control (Figure 14A). Both recombinant 
IFN-β and IFN-λ stimulated a robust ISRE activity (Vector + IFN v.s Vector alone) and 
interestingly UBXN6 further enhanced ISRE by ~2.5-3.4 times compared to the treated 
vector control, respectively (Figure 14 B, C).  
The ability of UBXN6 to activate ISRE was dose-dependent (Figure 15A).  We 
further confirmed the ISRE reporter assay by quantitative reverse transcription PCR (q-RT-
PCR). UBXN6 potentiated the mRNA expression of two well-established ISGs, including 
OAS1A and ISG15 (Figure 15B, C). These results demonstrate that UBXN6 is a unique 





Figure 14: Ectopic expression of UBXN6 enhances recombinant IFN induced ISRE 
activity.    
(A) Quantification of ISRE promoter activities by Dual-Luciferase assay in HEK293T cells 
transfected with either 100ng of vector or 100ng of individual FLAG-UBXN plasmids.  
The immunoblot of whole cell lysates depicts the expression levels of FLAG-UBXN proteins, and α-
Tubulin serves as a housekeeping protein control.  
(B) Quantification of ISRE promoter activities by Dual-Luciferase assay in HEK293T cells 
transfected with either 100ng vector or 100ng individual FLAG-UBXN plasmids 16hr after 10ng/ ml 




























































































































































































































































































(C) Quantification of ISRE promoter activities by Dual-Luciferase assay in HEK293T cells 
transfected with either 100ng vector or 100ng individual FLAG-UBXN plasmids 16hr after 10ng/ ml 
of human IFN- β1 stimulation.  
Data represent the mean ± SEM (n = 3), Student’s t-Test:  two tailed distribution, two-sample 







Figure 15: Ectopic expression of UBXN6 enhances IFN-I/III-induced ISRE activity and ISG 
expression in a  dose-dependent manner.  
(A) Quantification of ISRE promoter activities by Dual-Luciferase assay in HEK293T cells 
transfected with either increasing doses of vector or increasing doses of FLAG-UBXN6 plasmid 
16hr after 10ng/ ml of human IFN-λ stimulation.  
(B, C) mRNA expression of interferon-stimulated gene ISG15 and OAS1A 16hrs after IFN-β 
stimulation as quantified by qPCR analysis.  
Data represent the mean ± SEM (n = 3), Student’s t-Test:  two tailed distribution, two-sample 












































































































4.2 Aim 2: To characterize the function of UBXN6 in viral pathogenesis and host 
innate immune responses. 
 
 The screening from Aim 1, I hypothesized that UBXN6 positively regulates RNA 
virus-induced IFN-I/III responses. To validate the results from the UBXN6 overexpression 
studies, we evaluated IFN-I/III expression and viral replication in UBXN6 deficient cells. 
Two approaches were undertaken for gene silencing; gene knockdown by siRNA and gene 
knockout by CRISPR-Cas9 technology. We have established the protocol for the 
generation of knockout cells by CRISPR technology. The HEK293 and trophoblast 
knockout cells (indicated as UBXN6-/- hereafter) were used to explore the function of this 
gene in IFN-I/III responses and viral replication. 
 
4.2.1 Sub-aim 2.1: To determine the role of UBXN6 in host immune responses by 
siRNA knockdown of UBXN6. 
 
 We depleted UBXN6 by three individual siRNAs against UBXN6 and MAVS as a 
control, followed by transfection with ∆RIG-I. We observed a moderate decrease in ISRE 
activity in UBXN6-depleted cells (Figure 16A). The knockdown efficiency of specific siRNA 
was about 50% (Figure 16B). Hence, we next used a mixture of all three siRNA for 
transfecting HEK293. We overexpressed MDA5, MAVS, and TBK1 of the RLR pathway to 
activate IFNB1 transcription in UBXN6-depleted cells. We observed a nonsignificant 
decrease in ISRE activity in UBXN6-depleted cells. Also, the IFNB1 mRNA levels were not 
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significantly reduced in UBXN6-depleted cells (Figure 17), suggesting that UBXN6 is not 





 A     B 
 
Figure 16: RNA interference of UBXN6 moderately affects RIG-I-induced ISRE activity.  
(A) Quantification of ISRE promoter activities by Dual-Luciferase assay. HEK293T cells were 
transfected with either scrambled (control) or UBXN6-specific siRNA, and after 48 hours the cells 
were transfected again with either vector or ∆ RIG-I and reporter plasmids. Luciferase activity was 
measured 16 hrs after the second transfection.  












































































Figure 17: RNA interference of UBXN6  modestly affects the primary RLR pathway.  
(A) Quantification of ISRE promoter activities by Dual-Luciferase assay in HEK293T cells 
transfected with either scrambled (control) or UBXN6 specific siRNA and after 48 hours 
transfected again with either vector or MAVS, TBK1, IRF3-5D.  
Quantification of siRNA knockdown efficiency as measured by qPCR using UBXN6 specific primers. 

























































































4.2.2 Sub-aim 2.2: To generate UBXN6 knockout in HEK293 and trophoblast cells by 
CRISPR-Cas9 technology and to examine host immune response as well as a viral 
infection in UBXN6 knockout cells. 
 
We next generated UBXN6 knockout in HEK293T and human trophoblasts cell 
lines using the CRISPR-Cas9 technology. Western blotting shows successful loss of UBXN6 
protein expression (Figure 18).  Thus, the knockout efficiency at protein level was 
established. 
 Next, we employed two models of RNA viruses, VSV and EMCV, to study the 
UBXN6 antiviral function. Both viruses induce IFN-I/III and ISGs primarily via the RLRs. A 
transcriptional unit encoding green fluorescent protein (GFP) is incorporated into the VSV 
genome upstream of the L polymerase to facilitate viral detection by fluorescence 
microscopy (Dalton and Rose, 2001) .  UBXN6-/- cells produced more intracellular VSV- 
GFP as observed by Fluorescent microscopic images (Figure 19). Consistently, UBXN6-/- 
cells produced more intracellular VSV RNA as measured by qPCR and increased 
extracellular infectious viral particles than UBXN6+/+ cells as quantified by plaque assay 
(Figure 20).  IFN-β and IFN-λ concentrations produced by UBXN6-/- cells were much lower 
than UBXN6+/+ cells in VSV infected cells (Figure 21).  
 Similar results were noted with EMCV infection. UBXN6-/- cells produced more 
intracellular EMCV RNA as measured by qPCR and increased extracellular infectious viral 






Figure 18: Abrogation of UBXN6 protein in trophoblast and HEK.  
Immunoblots showing UBXN6 and housekeeping Tubulin in UBXN6+/+, UBXN6-/- 1 and UBXN6-/- 2 





























































Figure 19: UBXN6 interferes with VSV infection. 
Fluorescent microscopic images of UBXN6+/+, UBXN6-/- 1 and UBXN6-/- 2 trophoblasts infected with 

















Figure 20: Viral replication is increased in UBXN6-/- trophoblasts.    
(A) Quantification of intracellular VSV RNA at 12 hours after infection by qPCR. 
(B) Quantification of the viral titers at 12hrs after VSV infection by plaque assay. 
Data represent the mean ± SEM (n = 3), Student’s t-Test:  two tailed distribution, two-sample 




































































































Figure 21: IFN-I/III induction by VSV is impaired in UBXN6-/-  trophoblasts.  
 (A) ELISA of IFN-β1 secreted from UBXN6+/+, UBXN6-/- 1 and UBXN6-/- 2 trophoblasts 0, 12, and 24 
hours after VSV infection.  
(B) ELISA of IFN-λ2 secreted from UBXN6+/+, UBXN6-/- 1 and UBXN6-/- 2 trophoblasts 0, 12, and 24 
hours after VSV infection.  
Data represent the mean ± SEM (n = 3), Student’s t-Test:  two tailed distribution, two-sample 


































































Figure 22: EMCV replication is increased in UBXN6-/- trophoblasts.  
 (A) Quantification of intracellular viral RNA at 12 hours after infection by qPCR. 
(B) Quantification of the viral titers at 12 hrs after infection by plaque assay. 
Data represent the mean ± SEM (n = 3), Student’s t-Test:  two tailed distribution, two-sample 































































































4.3 Aim 3: To find out the molecular mechanism by which UBXN6 resists viral 
infections and regulates the immune responses. 
 
 UBXN6 was shown to induce hIFN-β-, and hIFN-λ-stimulated ISRE promoter 
activity (from Aim 1-screen). This also indicates that the activity of Type I/III interferon-
induced JAK/STAT signaling pathway is enhanced by UBXN6. Hence, we hypothesize that 
UBXN6 can regulate IFN- JAK-STAT signaling pathway. 
 
4.3.1.1 Sub-aim 3.1: To test if recombinant hIFN-λ-induced ISG response is deficient in 
UBXN6-/- cells. 
 
We analyzed the expression of 84 genes related to IFN-I/III responses by PCR array 
in UBXN6+/+ and UBXN6-/-trophoblasts (Table 7). The fold change with each gene was 
shown in table 1. The volcano plot, heat map, and cluster-grams were used to identify 
changes in gene expression (Figure 23 A, B, D). Expression of ~20 ISGs including well-
characterized IFIT1, OAS1/2, IFITM1, ISG15 and DDX58 (encodes RIG-I) was >1.5 fold 
lower in UBXN6-/-   than UBXN6+/+ cells treated with recombinant IFN-λ for 6 hours. Three 
genes (IL6, VEGF, IFNE) that are not conventional ISGs were upregulated (Figure 23 C).  
The reduction in IFIT1 and OAS1 expression in HEK293 and trophoblasts was further 
validated by qPCR (Figure 24).    
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Table 7: The relative fold changes in all the tested genes from human IFN-I PCR array 
from UBXN6+/+ and UBXN6-/- 2 trophoblast cells 6hrs after 10ng/mL IFN-λ1 treatment. 








ADAR 0.89 ( 0.61, 1.17 ) 0.480 IL6 3.48 ( 2.71, 4.26 ) 0.000
BAG3 1.24 ( 0.94, 1.53 ) 0.159 IRF1 0.84 ( 0.61, 1.07 ) 0.287
BST2 1.29 ( 0.97, 1.60 ) 0.110 IRF2 1.24 ( 0.91, 1.57 ) 0.191
CASP1 0.88 ( 0.67, 1.08 ) 0.336 IRF3 1.20 ( 0.86, 1.55 ) 0.323
CAV1 0.50 ( 0.40, 0.61 ) 0.010 IRF5 1.28 ( 0.57, 1.99 ) 0.455
CCL2 0.69 ( 0.57, 0.81 ) 0.010 IRF7 0.54 ( 0.36, 0.73 ) 0.051
CCL5 0.93 ( 0.73, 1.13 ) 0.536 IRF9 0.86 ( 0.60, 1.12 ) 0.377
CD70 1.09 ( 0.84, 1.34 ) 0.529 ISG15 0.31 ( 0.22, 0.40 ) 0.010
CD80 0.95 ( 0.56, 1.33 ) 0.740 ISG20 0.39 ( 0.29, 0.49 ) 0.008
CD86 0.97 ( 0.57, 1.38 ) 0.993 JAK1 1.03 ( 0.82, 1.24 ) 0.859
CDKN1B 1.02 ( 0.70, 1.34 ) 0.990 JAK2 1.14 ( 0.86, 1.42 ) 0.394
CIITA 1.02 ( 0.63, 1.40 ) 0.926 MAL 1.03 ( 0.62, 1.43 ) 0.949
CRP 0.87 ( 0.56, 1.18 ) 0.406 MET 0.94 ( 0.66, 1.22 ) 0.656
CXCL10 1.08 ( 0.34, 1.82 ) 0.915 MNDA 0.84 ( 0.59, 1.08 ) 0.283
DDX58 0.39 ( 0.31, 0.47 ) 0.005 MX1 0.65 ( 0.44, 0.86 ) 0.049
EIF2AK2 0.68 ( 0.51, 0.85 ) 0.066 MX2 0.33 ( 0.25, 0.40 ) 0.005
GBP1 0.63 ( 0.49, 0.78 ) 0.037 MYD88 0.97 ( 0.67, 1.28 ) 0.780
HLA-A 0.90 ( 0.65, 1.16 ) 0.493 NMI 0.72 ( 0.57, 0.87 ) 0.053
HLA-B 0.66 ( 0.43, 0.89 ) 0.110 NOS2 1.06 ( 0.81, 1.32 ) 0.703
HLA-E 0.86 ( 0.64, 1.08 ) 0.322 OAS1 0.43 ( 0.36, 0.50 ) 0.003
HLA-G 0.97 ( 0.62, 1.32 ) 0.797 OAS2 0.35 ( 0.24, 0.46 ) 0.015
IFI16 0.72 ( 0.58, 0.87 ) 0.053 PML 0.52 ( 0.38, 0.67 ) 0.021
IFI27 0.63 ( 0.42, 0.84 ) 0.079 PRKCZ 0.99 ( 0.68, 1.31 ) 0.881
IFI30 1.02 ( 0.68, 1.36 ) 0.957 PSME2 1.07 ( 0.80, 1.35 ) 0.713
IFI6 0.29 ( 0.17, 0.41 ) 0.023 SH2D1A 1.12 ( 0.80, 1.44 ) 0.514
IFIH1 0.56 ( 0.40, 0.72 ) 0.035 SHB 1.18 ( 0.94, 1.43 ) 0.198
IFIT1 0.20 ( 0.14, 0.26 ) 0.006 SOCS1 0.96 ( 0.77, 1.15 ) 0.676
IFIT2 0.32 ( 0.23, 0.40 ) 0.008 STAT1 0.58 ( 0.41, 0.76 ) 0.044
IFIT3 0.30 ( 0.20, 0.40 ) 0.016 STAT2 0.64 ( 0.46, 0.83 ) 0.076
IFITM1 0.44 ( 0.35, 0.53 ) 0.007 STAT3 1.02 ( 0.76, 1.29 ) 0.973
IFITM2 0.81 ( 0.66, 0.97 ) 0.115 TAP1 0.68 ( 0.49, 0.86 ) 0.079
IFITM3 0.71 ( 0.56, 0.87 ) 0.064 TICAM1 1.12 ( 0.86, 1.38 ) 0.433
IFNA1 1.20 ( 0.86, 1.54 ) 0.299 TIMP1 0.79 ( 0.58, 1.00 ) 0.186
IFNA2 1.04 ( 0.54, 1.54 ) 0.782 TLR3 1.26 ( 0.90, 1.63 ) 0.178
IFNA4 1.28 ( 0.95, 1.62 ) 0.135 TLR7 0.90 ( 0.19, 1.61 ) 0.700
IFNAR1 0.90 ( 0.69, 1.11 ) 0.416 TLR8 1.04 ( 0.69, 1.40 ) 0.740
IFNAR2 1.08 ( 0.79, 1.36 ) 0.712 TLR9 1.05 ( 0.64, 1.46 ) 0.796
IFNB1 1.43 ( 0.92, 1.94 ) 0.123 TMEM173 0.71 ( 0.54, 0.87 ) 0.064
IFNE 1.59 ( 0.99, 2.18 ) 0.064 TNFSF10 0.95 ( 0.56, 1.35 ) 0.819
IFNW1 1.07 ( 0.77, 1.37 ) 0.573 TRAF3 0.92 ( 0.63, 1.22 ) 0.580
IL10 1.23 ( 0.50, 1.96 ) 0.546 TYK2 1.01 ( 0.70, 1.32 ) 0.986











































































































































Figure 23: PCR array of IFN response genes in UBXN6+/+ and UBXN6-/- 2 trophoblast cells 
6hrs after IFN-λ1  treatment. 
 (A) The volcano plot of relative fold change in all the tested genes. 
(B) The heat map of relative fold change in all the tested genes. 
(C) The bar graph of genes with a 1.5 or more-fold change in the expression (upregulation/ 
downregulation). 
(D) The cluster-gram of relative fold change in all the tested genes. 
Data represent the mean ± SEM (n = 3), Student’s t-Test:  two tailed distribution, two-sample 






















Figure 24: UBXN6 is critical for IFN-λ1 induced ISGs production in trophoblasts. 
(A) mRNA expression of IFIT1 and OAS1A at 0, 6, 12, 24 hrs after IFN-λ1 treatment in UBXN6+/+ and 
UBXN6-/- 1 HEK293 cell. 
(B) mRNA expression of IFIT1 and OAS1A at 0, 6, 12, 24 hrs after IFN-λ1 treatment in UBXN6+/+ and 
UBXN6-/- 2 trophoblasts. 
Data represent the mean ± SEM (n = 3), Student’s t-Test:  two tailed distribution, two-sample 
unequal variance (*p < 0.05; ** p < 0.01) 
 

















































































































































4.3.2 Sub-aim 3.2: To identify the molecular mechanism by which UBXN6 regulates 
IFN-I/III responses. 
 
 As the data mentioned above established the role of UBXN6 in positive regulation 
of IFN-I/III responses, we next investigated the mechanism by which it acts on the JAK-
STAT pathway.  The STAT1 phosphorylation was significantly reduced in UBXN6-/- 
trophoblast than UBXN6+/+ cells treated with recombinant IFN-λ for 60 minutes (Figure 
25). 
 Next, we performed immune-precipitation and mass spectrometry analysis to 
identify the UBXN6-interacting protein, which could be helpful for us to pinpoint the 
molecular mechanism (Table 8). Consistent with a previous report (Alexandru et al., 2008)  
UBXN6 bound to VCP with the highest affinity. Intriguingly, UBXN6 also pull-down CFL and 
PRMT5 with/without IFN-λ treatment. IFN-λ treatment slightly increased UBXN6-
PRMT5/CFL/VCP interaction. Of great interest, PRMT5 is an arginine methyltransferase 
that interacts with JAK1/2-TYK2 (Pollack et al., 1999) . It is thus possible that UBXN6 could 






Figure 25: UBXN6 regulates STAT1 phosphorylation.   
Immunoblot of p-STAT1 and STAT1 in the whole cell lysates of UBXN6+/+ and UBXN6-/- 2 
































Table 8: Identification of UBXN6-interacting proteins by immunoprecipitation and mass 
spectrometry analysis.   
HEK293T cells were transfected with either vector or FLAG-UBXN6 plasmid and treated with 
human IFN-β (10ng/ml) for 60 minutes. Whole cell lysates were immunoprecipitated with FLAG 
antibody-conjugated magnetic beads and the bound proteins were identified by mass 
spectrometry t. The total spectrum counts of bound proteins were normalized to input UBXN6 
counts. Fifty identified proteins were listed below, and three UBXN6-interacting proteins with the 
highest confidence were highlighted in yellow. 
              Total Spectrum Count       
























































































































































Transitional endoplasmic reticulum 
ATPase OS=Homo sapiens GN=VCP 
PE=1 SV=4 
TERA_H











Cluster of Heat shock protein HSP 
90-alpha OS=Homo sapiens 












Immunoglobulin kappa variable 2-29 












THO complex subunit 4 OS=Homo 





F 28   10 9 20 17 1 
1.




FLAG-UBXN6 OS=Homo sapiens 









Heat shock 70 kDa protein 1B 













Cluster of Tubulin beta chain 




N [3] TUBB 48 
TRU











Actin, cytoplasmic 2 OS=Homo 









Pyruvate kinase PKM OS=Homo 
sapiens GN=PKM PE=1 SV=4 
KPYM_





Alpha-enolase OS=Homo sapiens 
GN=ENO1 PE=1 SV=2 
ENOA_






methyltransferase 5 OS=Homo 















Cluster of Elongation factor 1-alpha 
1 OS=Homo sapiens GN=EEF1A1 












Cluster of Heat shock cognate 71 
kDa protein OS=Homo sapiens 




[2] HSPA8 71 
TRU





SCY1-like protein 2 OS=Homo 









Elongation factor 2 OS=Homo 
sapiens GN=EEF2 PE=1 SV=4 
EF2_HU





Eukaryotic translation initiation 
factor 4B OS=Homo sapiens 
GN=EIF4B PE=1 SV=1 
E7EX17
_HUMA





Protein phosphatase 1B OS=Homo 










78 kDa glucose-regulated protein 
OS=Homo sapiens GN=HSPA5 PE=1 
SV=2 
GRP78_
HUMAN HSPA5 72  
TRU











Tubulin alpha-1B chain OS=Homo 









Peroxiredoxin-6 OS=Homo sapiens 
GN=PRDX6 PE=1 SV=3 
PRDX6_





60S ribosomal protein L38 OS=Homo 
sapiens GN=RPL38 PE=1 SV=2 
RL38_H






2,6-bisphosphatase 2 OS=Homo 











Nucleolin OS=Homo sapiens GN=NCL 
PE=1 SV=3 
NUCL_H





Cluster of Keratin, type II 
cytoskeletal 1 OS=Homo sapiens 
GN=KRT1 PE=1 SV=6 (K2C1_HUMAN) 
K2C1_H
UMAN 
[5] KRT1 66 
TRU






ribonucleoprotein K OS=Homo 









60 kDa heat shock protein, 
mitochondrial OS=Homo sapiens 
GN=HSPD1 PE=1 SV=2 
CH60_H





Stress-70 protein, mitochondrial 
OS=Homo sapiens GN=HSPA9 PE=1 
SV=2 
GRP75_




















Polymerase delta-interacting protein 











40S ribosomal protein S25 OS=Homo 
sapiens GN=RPS25 PE=1 SV=1 
RS25_H





Heat shock 70 kDa protein 4 
OS=Homo sapiens GN=HSPA4 PE=1 
SV=4 
HSP74_







ATP synthase subunit beta, 
mitochondrial OS=Homo sapiens 
GN=ATP5B PE=1 SV=3 
ATPB_H





GTP-binding nuclear protein Ran 









60S ribosomal protein L35 OS=Homo 
sapiens GN=RPL35 PE=1 SV=2 
RL35_H





Serine/threonine-protein kinase 38 
OS=Homo sapiens GN=STK38 PE=1 
SV=1 
STK38_
HUMAN STK38 54 
TRU





Elongation factor Tu, mitochondrial 
OS=Homo sapiens GN=TUFM PE=1 
SV=2 
EFTU_H





60S ribosomal protein L23a 










40S ribosomal protein S3 OS=Homo 
sapiens GN=RPS3 PE=1 SV=2 
RS3_HU





RNA binding motif protein 10, 
isoform CRA_d OS=Homo sapiens 













ATP synthase subunit alpha, 
mitochondrial OS=Homo sapiens 









Histone H4 OS=Homo sapiens 









60S ribosomal protein L27 OS=Homo 
sapiens GN=RPL27 PE=1 SV=2 
RL27_H






ribonucleoproteins A2/B1 OS=Homo 









Multifunctional protein ADE2 
(Fragment) OS=Homo sapiens 
GN=PAICS PE=1 SV=1 
E9PBS1
_HUMA





Endoplasmin OS=Homo sapiens 




B1 92  
TRU





T-complex protein 1 subunit theta 
OS=Homo sapiens GN=CCT8 PE=1 
SV=4 
TCPQ_H






enzyme 1 OS=Homo sapiens 

















UBXN6 belongs to a family of proteins that are putatively involved in VCP-
mediated cellular processes. Recent studies suggest that  UBXN6 participates in ERAD 
(Nagahama et al., 2009) , protein trafficking(Haines et al., 2012 ;  Kirchner et al., 2013 ;  
Ritz et al., 2011) , clearance of ruptured lysosomes by autophagy (Papadopoulos et al., 
2017) , degradation of mitochondrial outer membrane protein myeloid cell leukemia 1 
(MCL1) in a model of Huntington's disease (Guo and Qi, 2017) . In this study, we identified 
that UBXN6 is the only positive regulator of JAK-STAT signaling amongst the 13 known 
UBXNs. 
We present several pieces of evidence showing that UBXN6 positively regulates 
the JAK1-STAT1/2 signaling pathway. First, UBXN6 overexpression potentiates ISG 
induction by recombinant IFN-β or IFN-λ, which activates JAK1-STAT1/2 signaling via their 
respective receptors. Second, ISG expression and STAT1 phosphorylation stimulated by 
IFNs is impaired in UBXN6-deficient cells. Third, IFN/ISG expression activated by polyIC 
and viral infection is also reduced in UBXN6 overexpression.   
Although our data suggest that UBXN6 regulates JAK1-STAT1/2 specifically, the 
observations that polyIC and virus-induced type I/III expression is also reduced in the 
UBXN6 deficient cells suggest a role of UBXN6 in the RLR signaling too. The two dominant 
polyIC/viral RNA receptors in human trophoblasts are melanoma differentiation-
associated gene 5, MDA5 (encoded by IFIH1), and retinoic acid-inducible gene-1, RIG-I 
(encoded by DDX58) (J. Ma et al., 2018b) , which are also well characterized ISGs. Their 
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basal levels are generally very low and need to be induced via JAK1-STAT1/2 in the 
context of polyIC/virus stimulation. Thus, a deficiency in JAK1-STAT1/2 signaling may also 
negatively impact primary IFN responses.  Indeed, STAT1/2 deficiency in mice led to a 
significant reduction in type I IFNs after dengue virus infection (Perry et al., 2011) .  To 
clarify this point, we overexpressed the major molecules (MDA5/MAVS/TBK1) of the RLR 
pathway to activate IFNB1 transcription independently of JAK1-STAT1/2. The results 
suggest that UBXN6 does not directly regulate the RLR pathway, rather directly targets 
JAK1-STAT1/2. This is further substantiated by the findings that JAK1/STAT1 
phosphorylation activated directly by recombinant IFN-λ1 was impaired in UBXN6-/- cells.  
Next, we investigated the molecular function of UBXN6. The significant reduction 
of STAT1 phosphorylation after IFN-β stimulation in UBXN6 deficient cells suggests that 
UBXN6 acts upstream in the pathway. By this hypothesis, we found that UBXN6 was able 
to bind to JAK-binding protein PRMT5, when over-expressed at a very low amount and 
stimulated with IFN-β. PRMT5 was identified as a JAK-binding protein and involved in 
arginine methyltransferase (Pollack et al., 1999) . PRMT5 was found to be involved in the 
regulation of NF-κB in TRAIL-induced apoptosis by competing with TRAIL to bind to DDR4. 
Another study reported that methylation of p65 subunit leads to the regulation of NF-κB 
activity (J. H. Kim et al., 2016) . However, we recognize that our current dataset cannot 
conclude a functional relationship between UBXN6, PRMT5, and JAK1/2.  At present, 
work is underway to elucidate this. We hypothesize that PRMT5 could be a dominant 
negative binder of JAK1/2 and UBXN6 binding to PRMT5 directly or as a complex of 
PRMT5-UBXN6-VCP (As in Figure 26) liberates JAK from the PRMT5-bound state. The free 
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JAK may undergo conformational changes and expose the phosphorylation sites or may 
provide docking to STAT for its activation. It is also possible that methylation or 
demethylation of arginine on JAK1/2 residues may enhance JAK phosphorylation and the 
downstream signaling. Thus, increased STAT phosphorylation is a possible mechanism by 
which UBXN6 can positively regulate JAK-STAT signaling.  
UBXN6 could also stimulate STAT phosphorylation by a PRMT5-JAK independent 
mechanism. UBXN6 may interact with TYK2, which is bound to the cytoplasmic domain of 
IFN receptors, resulting in enhanced kinase activity. Alternately, UBXN6-VCP complex may 
degrade inhibitors of JAK-STAT signalings, such as SOCSs, PTPs, and PIAs.  
Another predicted mechanism of positive regulation of JAK-STAT signaling by 
UBXN6 is via IFN receptors trafficking/recycling/degradation. Following receptor agonism, 
the C-terminus of IFNAR is phosphorylated, followed by its ubiquitination and 
internalization. Internalization can result in degradation of the receptor, thereby reducing 
membrane expression, or it can result in the recycling of the receptor without an 
extended impact on membrane receptor levels. However, clathrin-mediated endocytosis 
may also serve to concentrate the IFNAR receptors and signaling components, thereby 
amplifying signaling (Claudinon et al., 2007) . 
Many cells are responsive to type I IFNs because their receptors are ubiquitously 
expressed. In contrast, type III receptors are restricted to specific cell types such as 
mucosal epithelial, endothelial cells and human liver (Wack et al., 2015) . The 
trophoblasts act as a primary barrier of the placenta by constitutively secreting IFN-III. 
The medium from uninfected cells was found to protect nonplacental cells from Zika 
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infection. Trophoblast-derived IFN-III act as a barrier to Zika infection via autocrine as well 
as the paracrine mode and restrict viral entry to the fetal compartment (Bayer et al., 
2016) . Indeed, we found that increased ISG production in trophoblasts by recombinant 
IFN-λ1 stimulation was impaired in UBXN6-/- cells; confirming our findings that UBXN6 





Figure 26: A model depicting UBXN6 association with the only PRMT5 or as a complex of 






 The UBX domain-containing proteins (UBXN) are involved in various cellular 
processes including ubiquitin-dependent protein degradation, vesicle fusion, and cell 
cycle control. However, their role in the regulation of the innate immune pathways has 
not been thoroughly explored. We demonstrate that the UBXN6 positively regulates type 
I/III interferons (IFN-I/III)- induced Janus kinase/signal transducers and activators of 
transcription (JAK/STAT) pathway. IFN-I/III induce expression of several ISGs through 
theJAK/STAT pathway to combat viral infections.  
 Amongst 13 known UBXNs, ectopic expression of UBXN6 highly enhances IFN-β 
and IFN-λ1-stimulated ISG.  UBXN6 -/- HEK293 and trophoblasts were deficient in ISG 
production upon IFN-λ1 stimulation. Also, RNA virus replication increased in UBXN6 -/- 
cells compared to UBXN6 +/+ cells, and this was accompanied by a reduction in both IFN-
I/III and ISG expression. The IFN responses to a dsRNA analogue polyinosinic-polycytidylic 
acid were also decreased. Phosphorylation of STAT1 induced by recombinant IFN-λ1 was 
impaired in UBXN6 deficient cells. These results demonstrate that UBXN6 restricts viral 
infection through optimal activation of JAK1-STAT1/2 signaling.    
 Mass spectrometry analysis revealed the association of UBXN6 with PRMT5, a JAK-
binding protein. It is suggested that binding of UBXN6 to PRMT5 affect JAK activity and its 
downstream signaling. Further mechanistic studies are required to confirm the target of 
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UBXN6 in JAK-STAT signaling. Also, the role of PRMT5 when associated with UBXN6 needs 
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